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Abstract		
Obsessive-compulsive	disorder	(OCD)	is	common,	emerges	early	in	life	and	tends	to	run	a	chronic,	
impairing	course.	Despite	the	availability	of	effective	treatments,	the	duration	of	untreated	illness	(DUI)	
is	high	(up	to	around	10	years	in	adults)	and	is	associated	with	considerable	suffering	for	the	individual	
and	their	families.	This	consensus	statement	represents	the	views	of	an	international	group	of	expert	
clinicians,	including	child	and	adult	psychiatrists,	psychologists	and	neuroscientists,	working	both	in	high	
and	low	and	middle	income	countries,	as	well	as	those	with	the	experience	of	living	with	OCD.	The	
statement	draws	together	evidence	from	epidemiological,	clinical,	health	economic	and	brain	imaging	
studies	documenting	the	negative	impact	associated	with	treatment	delay	on	clinical	outcomes,	and	
supporting	the	importance	of	early	clinical	intervention.	It	draws	parallels	between	OCD	and	other	
disorders	for	which	early	intervention	is	recognized	as	beneficial,	such	as	psychotic	disorders	and	autism	
spectrum	disorders,	as	well	as	impulsive-compulsive	disorders	associated	with	problematic	usage	of	the	
Internet,	for	which	early	intervention	may	prevent	the	development	of	later	addictive	disorders.	It	also	
generates	new	heuristics	for	exploring	the	brain-based	mechanisms	moderating	the	‘toxic’	effect	of	an	
extended	DUI	in	OCD.	The	statement	concludes	that	there	is	a	global	unmet	need	for	early	intervention	
services	for	OC	related	disorders	to	reduce	the	unnecessary	suffering	and	costly	disability	associated	
with	under-treatment.		New	clinical	staging	models	for	OCD	that	may	be	used	to	facilitate	primary,	
secondary	and	tertiary	prevention	within	this	context	are	proposed.	
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Vignette		
I	first	had	OCD	symptoms	when	I	was	17.	Intensely	worried	and	not	daring	to	speak	to	anyone	about	my	
disturbing	intrusive	thoughts,	I	hesitated	and	then	went	to	see	a	psychologist	for	help.	Unfortunately,	she	
failed	to	discuss	the	diagnosis	of	OCD	with	me	and	put	me	through	an	extensive	program	of	Freudian	
psychoanalysis,	which	only	made	me	worse.		
The	OCD	waxed	and	waned	for	several	years,	until	I	had	a	major	relapse	around	the	birth	of	my	second	
son,	when	I	was	30.	This	time,	a	friend	lent	me	a	book,	which	led	me	to	a	self-diagnosis	of	OCD.			
I	immediately	went	to	my	GP,	who	agreed	with	my	diagnosis.	But	with	waiting	lists	too	long	for	talking	
therapies,	I	went	private.	I	saw	a	specialist	in	cognitive	behavioral	therapy	(CBT)	who	took	me	through	a	
program	of	exposure	and	response	prevention	that	eventually	helped	me	overcome	that	particular	
relapse.		
I’ve	had	many	relapses	since	then,	sometimes	with	crippling	depression	that	has	left	me	suicidal.	
Medications	–	particularly	clomipramine	–	have	helped	with	the	depression,	while	subsequent	courses	of	
CBT	have	helped	me	manage	my	OCD.	
Had	I	got	a	correct	diagnosis	and	treatment	from	the	start,	I’m	convinced	my	subsequent	relapses	
wouldn’t	have	been	as	bad.	That’s	why	I	believe	that	early	diagnosis	and	treatment	are	key.	
	
	
	
	
	
Introduction		
Obsessive-compulsive	disorder	(OCD)	represents	one	of	the	most	common,	chronic,	costly	and	
burdensome	brain	disorders,	in	terms	of	the	personal	impact,	direct	treatment-related	costs	and	the	
indirect	costs	related	to	lost	productivity	(Hollander	et	al	2016).	Commonly	emerging	in	childhood	or	
adolescence	(Dell’Osso	et	al.,	2016a),	the	disorder	is	associated	with	substantial	distress,	treatment-
seeking	activity,	functional	disability	and	suicidality	(Carmi	et	al.,	2019).	Evidence-based	treatments	
include	cognitive	behaviour	therapy	(CBT)	and	pharmacological	treatment	with	serotonin	reuptake	
inhibitors	(Skapinakis	et	al.,	2016a).	In	cases	where	family	accommodation	of	symptoms	appears	
problematic,	specific	involvement	of	family	members	in	the	treatment	plan	can	be	helpful.	Although	
studies	suggest	that	recovery	can	be	a	realistic	goal	for	a	subgroup	of	the	OCD	population	(Burchi	et	al.,	
2018),	‘real	world’	clinical	outcomes	are	often	disappointing.	Relapse	rates	are	high	and	fewer	than	40%	
of	treatment-seeking	adults	with	OCD	are	reported	to	achieve	a	sustained	remission	when	followed	up	
long-term	(Eisen	et	al.,	2013,	Skoog	G	and	Skoog	I,	1999).	In	a	thirty	years	follow-up	study	of	largely	non-
treatment	seeking	cases	of	obsessive-compulsive	disorders	and	syndromes,	the	median	duration	of	OCD	
was	16y,	roughly	one-third	of	OCD	cases	did	not	remit	and	a	poorer	prognosis	for	remission	was	seen	in	
those	with	more	severe	or	longer	duration	of	illness,	psychiatric	comorbidity	and	those	seeking	
professional	help	(Fineberg	et	al	2013c)).			
	
OCD	in	childhood	clinical	samples	also	shows	high	rates	of	persistence	despite	treatment	provision	
(Stewart	et	al.,	2004;	Zellmann	et	al.,	2009).	In	the	meta-analysis	of	childhood	studies	by	Stewart	and	
colleagues	(2004),	the	pooled	mean	persistence	rates	were	41%	for	full	OCD	and	60%	for	full	or	
subthreshold	OCD.	Epidemiological	studies	also	suggest	moderate	stability	of	OC	symptoms	in	children,	
with	genetic	as	well	as	environmental	factors	contributing	to	persistence	and	remission	(van	Grootheest	
et	al.,	2007).	In	the	study	of	Mancebo	and	colleagues	(2014),	a	shorter	latency	to	initiation	of	OCD	
treatment	was	associated	with	faster	onset	of	remission.		Indeed,	converging	evidence	from	multiple	
centres	indicates	that	a	longer	duration	of	untreated	OCD	(as	opposed	to	an	early	onset	of	illness)	is	
associated	with	increased	clinical	comorbidity	and	functional	disability,	as	well	as	significantly	poorer	
treatment-related	clinical	outcomes	including	treatment	response	and	remission	(Dell’	Osso	et	al.,	
2013a;	2016a,	Albert	et	al.,	2018a	(in	submission),	b;	Rufer	et	al.,	2005).		
	
Most	cases	of	OCD	arise	before	the	age	of	18y	(Fineberg	et	al.,	2013,	Ruscio	et	al.,	2010,	Rapoport	et	al.,	
2000,	Dell’Osso	et	al.,	2016a),	and	the	duration	of	untreated	illness	(DUI)	for	OCD	remains	one	of	the	
highest	for	any	severe	mental	disorder	(Altamura	et	al.,	2010).	Most	adults	with	OCD	have	been	
suffering	for	more	than	10	years	before	effective	treatment	is	initiated	(Garcia-Soriano	et	al.,	2014,	
Albert	et	al.,	2018a).	In	the	case	of	children	and	adolescents,	the	diagnosis	is	also	often	missed	
(Rapoport	et	al.,	2000),	and	the	lag	between	the	onset	of	OCD	and	ascertainment	of	the	diagnosis	is	
reported	by	some	specialized	centres	to	lie	at	two	to	three	years	(Geller	et	al.,	2000).	The	average	DUI	
also	exceeds	two	to	three	years	(Walitza	et	al.,	2008;	Zellmann	et	al.,	2009).	This	is	a	relatively	long	
delay,	given	that	the	average	patient	age	in	these	samples	was	only	13	years.		
	
Brain	imaging	has	identified	neuro-circuitry	abnormalities	associated	with	OCD	appearing	to	evolve	as	
transition	from	childhood	to	adulthood	occurs.		In	children	and	adolescents	with	OCD,	similar	altered	
functional	activations	in	the	same	brain	regions	of	affective	and	cognitive	cortico-striatal-thalamic	(CST)	
circuits	exist	as	in	adult	OCD	patients	(Brem	et	al.,	2012).	However,	a	large	mega-	and	meta-analysis	of	
imaging	data	from	multiple	sites	found	that	the	brain	alterations	became	more	heterogeneous	and	
complex	with	increasing	age,	suggesting	that	OCD	is	underpinned	by	complex,	nonlinear	
neurodevelopmental	mechanisms	(Boedhoe	et	al.,	2018,	Boedhoe	et	al.,	2017).	Arguably,	early	
intervention,	bringing	with	it	the	potential	for	improved	symptom-control,	could	help	to	interrupt	the	
progression	of	such	brain-based	changes,	though	as	yet	we	do	not	have	imaging	data	to	support	this.				
	
By	missing	out	on	timely,	effective	treatment,	the	majority	of	people	with	OCD	can	be	expected	to	
endure	many	years	of	chronic	or	relapsing	illness.	Intervention	aimed	at	delivering	early	accurate	
detection	and	diagnosis	accompanied	by	targeted	evidence-based	interventions,	could	be	expected	to	
produce	more	clinically	and	cost	effective	outcomes	(Brakoulias	et	al.,	2018).	Using	similar	arguments,	
early	intervention	teams	for	psychosis	are	well-established	in	America,	Europe	and	Australasia	(Edwards	
et	al.,	2002,	NICE	UK	https://www.england.nhs.uk/mentalhealth/wp-content/uploads/.../eip-
guidance.pdf)).		
	
This	consensus	statement,	representing	the	views	of	an	international	group	of	expert	clinicians,	
scientists	and	people	with	lived	experience	of	OCD,	draws	together	evidence	suggesting	that	greater	
emphasis	on	targeted	early	intervention,	appropriately	delivered	within	mental	health	services,	is	also	
required	for	people	suffering	with	OCD.	We	propose	new	staging	models		for	OCD,	including	prototypical	
criteria	for	early	prodromal	stages	of	the	illness,	as	one	of	the	first	steps	toward	the	development	of	
early	intervention	strategies.	We	hope	this	statement	will	have	a	positive	influence	on	clinicians’	
practice.	We	note,	for	example,	results	of	a	survey	among	Danish	clinicians	suggesting	that	clinical	
recommendations	on	assessment	and	treatment	for	children	and	adolescents	with	OCD	could	be	
translated	into	positive	clinical	outcomes	(Nissen	and	Thomsen,	2008).		
	
Methods		
In	developing	this	consensus	statement,	a	working	group	was	selected	from	among	the	members	of	the	
European	College	of	Neuropsychopharmacology	(ECNP)	Obsessive	Compulsive	and	Related	Disorders	
Research	Network	(OCRN),	the	International	College	of	Obsessive	Compulsive	Spectrum	Disorders	
(ICOCS)	and	the	World	Psychiatric	Association	Anxiety	and	Obsessive	Compulsive	Disorders	Section.	The	
group	comprised	expert	clinicians,	including	child	and	adult	psychiatrists,	psychologists	and	
neuroscientists,	including	those	working	in	high,	low	and	middle	income	countries,	and	included	an	
individual	with	the	experience	of	living	with	OCD.	The	group	performed	a	narrative	review	of	the	
scientific	literature	pertaining	to	the	cost	and	burden	of	OCD	across	the	lifespan,	the	duration	of	
untreated	illness	(DUI)	and	its	impact	on	health	and	wellbeing	outcomes,	and	the	potential	role	of	early	
intervention,	from	various	perspectives	reflecting	their	experience	and	expertise.		After	several	
iterations,	a	draft	was	circulated	among	the	extended	membership	of	the	aforementioned	organisations	
and	further	comments	were	integrated.		A	final	document	was	presented,	discussed	and	provisionally	
endorsed,	subject	to	minor	amendments,	by	around	40	delegates	in	a	symposium	programmed	within	
the	14thAnnual	Scientific	Meeting	of	the	ICOCS,	held	in	association	with	the	ECNP	OCRN,	Barcelona,	
October	10th	2018.		
	
Epidemiology	of	OCD	
OCD	has	an	estimated	lifetime	prevalence	of	2	–	3%	under	DSM-III,	DSM-III-R	and	DSM-V	criteria	(Robins	
et	al.,	1984;	Weissman	et	al.,	1994,	Ruscio	et	al.,	2010).	Some	epidemiological	surveys	of	US	and	
European	citizens,	using	diagnostic	instruments	aligned	with	the	DSM-IV,	produced	more	conservative	
estimates	of	lifetime	prevalence	of	respectively	1.6%	(Kessler	et	al.,	2005a)	and	0.8%	(Wittchen	et	al.,	
2011).	Another	epidemiological	survey	(Kessler	et	al.,	2011),	possibly	capturing	a	broader	spectrum	of	
cases,	estimated	the	lifetime	prevalence	at	5.8%	and	6.2%	in	low	and	high	income	countries	
respectively.	Indeed,	other	epidemiological		surveys	have	estimated	the	prevalence	of	subclinical	OC	
syndromes	at	between	7	–	25%	(Bebbington	et	al.,	1998,	Fullana	et	al.,	2009;	Fullana	et	al.,	2010;	
Fineberg	et	al.,	2013a).	Fullana	and	colleagues	(2009)	analysed	the	20-year	prospective	Dunedin	study	of	
an	unselected	birth-cohort	aged	11	to	32	years.	Consistent	with	the	US	National	Comorbidity	data	
(Ruscio	et	al.,	2010),	DSM-IV	OCD	was	reported	in	2.3%	of	the	sample	at	age	26	years	and	1.8%	at	age	32	
years,	whereas	sub-syndromal	obsessions	and	compulsions,	affecting	up	to	25%	of	the	cohort,	were	also	
found	to	be	associated	with	significant	impairment	and	help-seeking	behaviour.		
Obsessions	and	compulsions	often	have	their	roots	in	childhood	and,	if	persistent,	are	associated	with	
psychosocial	impairment	(Fullana	et	al.,	2009)	including	interference,	risk	of	comorbidity	and	help-
seeking,	irrespective	of	whether	or	not	the	diagnostic	threshold	for	OCD	is	met.	According	to	a	UK	
survey	of	children	and	adolescents	(Heyman	et	al.,	2001),	OCD	was	rare	in	younger	children	and	
increased	towards	adult	rates,	around	2%,	by	puberty.	Moreover,	the	presence	of	obsessive-compulsive	
(OC)	symptoms	at	11	years	predicted	a	high	risk	of	OCD	and	more	severe	symptomatology	in	adulthood.	
Thus,	sub-syndromal	OC	symptoms	are	common,	associated	with	distress	or	impairment,	may	presage	
the	onset	of	OCD	and	therefore	represent	a	potential	target	for	intervention.		
The	most	common	age	at	onset	of	OCD	was	historically	reported	to	occur	around	20	–	30	years	(Pollitt	
1957;	Ruscio	et	al.,	2010,	Altamura	et	al.,	2010).	However,	there	appear	to	be	two	peaks	of	incidence,	
one	with	a	pre-adolescent	onset	(mean	age	9-10	±2.5	years,	Geller	et	al.,1998;		mean	age	11	years,	
Taylor,	2011),	and	another	in	early	adulthood	(mean	age	23	years,	Taylor,	2011).	Approximately	three-
quarters	of	cases	(76%)	included	in	a	meta-analysis	demonstrated	an	early	onset	of	OCD	(Taylor,	2011).	
Other	studies	report	an	infrequent	onset	after	30	years	(Grant	et	al.,	2007).	In	a	thirty	year	prospective	
epidemiological	study	(Fineberg	et	al.,	2013a),	although	full	OCD	could	not	be	identified	before	10	years	
of	age,	sub-threshold	cases	were	retrospectively	reported	as	early	as	two	years	of	age,	around	two	
thirds	of	OCD	cases	had	emerged	by	the	age	of	22	years,	and	no	new	cases	of	OCD	developed	after	age	
37	years.	There	was	a	clear	increase	in	professional	treatment	related	to	OC	severity.	Lesser	OC	
symptomatology	tended	to	show	an	earlier	age	of	onset	than	OCD,	and	OCD	was	frequently	preceded	by	
sub-diagnostic	OC-symptoms.	Suicidality	and	serious	workplace	problems	were	substantially	associated	
with	OC	symptomatology,	notably	with	OCD	(OR	=	4.10	and	4.61	for	suicidality	and	workplace	problems,	
respectively).	However,	similar	to	the	childhood	data	(Fullana	et	al.,	2009),	those	with	lesser	OC	
symptomatology,	comprising	20%	of	the	community	sample,	also	reported	significant	suffering.		
	
Whereas	OCD	is	over-represented	in	females	in	community	studies	(around	1.5:1),	males	are	over-
represented	in	those	with	early	onset	of	illness	(Fineberg	et	al.,	2013a).	Evidence	from	studies	on	
convenience		samples	suggests	that	early	onset	OCD	is	associated	with	a	number	of	distinguishing	
features,	of	relevance	for	clinical	intervention,	including	comorbidity	with	neurodevelopmental	
disorders	such	as	tic	disorder	and	attention	deficit	hyperactivity	disorder	(ADHD)		and	familial	clustering	
suggesting	a	greater	genetic	contribution	(Walitza	et	al.,	2008,	Walitza	et	al.,	2010,	Taylor	2011).	Indeed,	
in	some	studies,	early-onset	OCD	has	been	associated	with	specific	gene	variants	of	serotonergic,	
dopaminergic	and	glutamatergic	receptors	and	synaptic	brain	related	genes,	neurotrophic	and	
transcription	factors	(Walitza	et	al.,	2014,	Grünblatt	et	al.,	2017).	Symmetry,	ordering	and	sexual	or	
religious	symptoms	are	also	associated	with	early-onset	OCD	(Labad	et	al.,	2008),	possibly	linked	to	
comorbidity	with	tic	disorders	and	tic-specific	symptoms.	Later	onset	cases	include	females	developing	
OCD	in	pregnancy,	after	parturition	or	miscarriage,	where	the	diagnosis	is	often	missed	(Williams	and	
Koran,	1997).	Prospective	studies	in	postpartum	females	have	shown	an	incidence	of	OCD	ranging	from	
4%	to	11%,	with	some	evidence	suggesting	avoidant	and	obsessive-compulsive	personality	traits	
predicted	postpartum	risk	(House	et	al.,	2016). Thus,	early	onset	and	later	onset	OCD	seem	to	be	
distinguishable	in	terms	of	gender,	comorbidity	and	genetics,	and	this	may	be	of	relevance	for	planning	
therapeutic	intervention.	
	
The	burden	and	costs	of	untreated	OCD		
When	 making	 medical	 and	 policy	 decisions,	 including	 the	 introduction	 of	 early	 interventions	 and	
services,	the	burden	of	a	disorder	in	terms	of	mortality,	comorbidity,	disability	and	effects	on	the	quality	
of	 life,	 as	 well	 as	 the	 cost	 of	 interventions	 and	 their	 effectiveness,	 are	 of	 paramount	 importance.	
Although	health	economic	studies	in	OCD	are	still	limited,	some	data	are	available,	helping	to	shed	light	
on	this	matter.		
	
	
A	strong	consensus	of	scientific	opinion	emphasizes	 the	negative	 impact	of	OCD	on	the	quality	of	 life,	
wellbeing	and	global	functioning	of	affected	patients	and	their	related	caregivers	(Macy	et	al.,	2013).	A	
number	of	studies	have	examined	quality	of	life	(QoL)	in	OCD	and	several	comprehensive	reviews	have	
been	 carried	 out	 (Coluccia	 et	 al.,	 2016;	Macy	 et	 al.,	 2013;	 Subramaniam	 et	 al.,	 2013;	 among	 others).	
Patients	 with	 OCD	 show	 a	 poorer	 QoL	 than	 healthy	 controls	 and	 the	 population	 in	 general.	 Further,	
when	OCD	has	been	compared	with	other	mental	or	physical	conditions,	some	studies,	although	not	all,	
have	 found	 that	 the	 effects	 of	 OCD	 on	 QoL	 are	 similar	 to	 those	 of	 serious	 mental	 illnesses	 such	 as	
schizophrenia	 (Macy	 et	 al.,	 2013;	 Subramaniam	et	 al.,	 2013).	 The	QoL	domains	most	 affected	 in	OCD	
include	 social	 relationships,	 including	 emotional	 and	 psychological	 components.	 Physical	 domains,	
although	impaired,	are	usually	less	affected.		
	Two	 key	 factors	 reported	 to	 influence	 QoL	 in	 OCD	 include	 disease	 severity	 and	 comorbidity.	 The	
association	 between	 OCD	 severity	 and	 QoL	 impairment	 is	 seen	 to	 affect	 even	 subclinical	 samples	
(Fullana	 et	 al.,	 2009,	 Fineberg	 et	 al.,	 2013a).	 Comorbid	 conditions,	 such	 as	 anxiety	 disorders,	 mood	
disorders	 or	 OC	 related	 disorders	 (OCRDs),	 which	 are	 very	 frequent	 in	 OCD	 patients,	 have	 a	 highly	
significant	 impact	 on	 lowering	QoL.	 Importantly,	 treatment	 studies	 have	 shown	 that	 improvement	 in	
OCD	is	associated	with	an	increase	in	QoL.	Hollander	and	colleagues	(2010)	showed	that	disability	and	
QoL	 significantly	 improved	 in	 patients	 showing	 a	 positive	 symptomatic	 treatment-response,	 and	 was	
significantly	better	compared	to	non-responders	or	those	who	experienced	a	relapse.	Therefore,	OCD,	
even	 at	 subclinical	 levels,	 involves	 a	 substantial	 decrease	 in	 QoL,	 which	 significantly	 improves	 with	
effective	treatment	and	improvement	of	the	condition.	
	
Studies	 focusing	 on	 disability	 have	 also	 demonstrated	 the	 substantial	 impact	 of	 OCD.	 Wittchen	 and	
colleagues	(2011)	examined	the	disability	adjusted	life	years	lost	(DALY)	associated	with	a	broad	range	of	
mental	 and	 neurological	 illnesses	 in	 Europe.	 Although	 the	 study	 reported	 a	 lower	 prevalence	 of	OCD	
(0.7%)	 than	 is	 usually	 reported	 in	 epidemiological	 studies,	 OCD	 accounted	 for	 329,684	 DALYs,	 which	
means	a	rate	of	7.9	DALYs	per	10,000	persons,	i.e.	higher	than	that	reported	in	epilepsy	(6.9),	although	
lower	 than	 that	 of	 unipolar	 depression	 (10.3),	 which	 showed	 the	 highest	 disability.	 Indeed,	 the	 high	
rates	 of	 comorbidity	 usually	 existing	 between	 OCD	 and	 depression	 suggests	 that	 those	 with	 both	
conditions,	who	may	show	even	higher	levels	of	disability	than	those	with	‘pure’	illness,	might	have	been	
included	 in	 the	depression	group	only,	 thus	underestimating	 the	 true	 impact	of	OCD.	Rates	of	under-
employment	 ranging	 from	 22%	 to	 as	 high	 as	 38%	 have	 been	 reported	 among	 OCD	 subjects	 in	
community	 and	 clinical	 samples	 (Mancebo	 et	 al.,	 2008).	 Early	 intervention	 could	 thus	 be	 expected	 to	
reduce	burden	and	costs	of	OCD,	for	example,	by	treating	frequently	co-occurring	depression	early.	
	
Although	 research	 into	 the	costs	of	 treated	and	untreated	OCD	 is	 scarce,	 the	existing	data	emphasise	
the	 significant	 indirect	 costs	 of	 OCD,	 such	 as	 loss	 of	 employment	 productivity,	 and	 the	 highly	 cost-
effective	impact	of	effective	treatment	(Hollander	et	al.,	2016).	For	example,	historical	data	estimating	
the	 1990	 total	 costs	 of	 OCD	 in	 the	 USA	 found	 that	 indirect	 costs,	 reflecting	 lost	 productivity	 of	
individuals	suffering	from	residual	OCD,	represented	74%	of	the	total	economic	cost	of	OCD	(Dupont	et	
al.,	1995).	Another	analysis	by	Knapp	and	colleagues	(2002),	which	examined	health	service	utilization,	
including	 mental	 health	 expenditure,	 inpatient	 hospitalization	 and	 ambulatory	 services,	 other	 formal	
care	 services,	 lost	 employment	 and	 education,	 family	 and	 caregiver	 impact,	 mortality,	 and	 transfer	
payments,	concluded	that	the	economic	consequences	of	OCD	were	widespread,	long	lasting,	and	often	
profound,	 involving	not	only	the	direct	costs	of	treatments	and	health	services	utilization,	but	also	the	
indirect	 effects	 on	 personal	 income,	 the	 ability	 to	 work,	 productive	 contributions	 to	 the	 national	
economy	and	impoverishment	of	quality	of	life.		
	
Preliminary	studies	using	health	economic	modelling	have	suggested	 that	 the	 treatment	of	OCD	using	
standard	 pharmacological	 or	 psychological	 therapies,	 or	 their	 combination,	 is	 cost-effective.	 Two	
analyses	(Skapinakis	et	al.,	2016b,	Fineberg	et	al.,	2018)	estimated	that	SSRIs	represented	the	most	cost-
effective	 option,	 whereas	 the	 other	 (National	 Institute	 for	 Health	 and	 Clinical	 Excellence,	 2006),	
estimated	that	the	combined	option	was	the	most	cost-effective.	Further	studies	designed	to	test	real-
world	 effectiveness	 and	 cost-efficiency	 are	 indicated	 to	 confirm	 the	 relative	 cost	 effectiveness	 of	 all	
standard	treatment	modalities	with	greater	certainty	(Fineberg	et	al.,	2018).		
	Duration	of	untreated	illness	in	OCD		
Lack	or	delayed	initiation	of	treatment	are	thought	to	play	a	relevant	role	in	the	overall	burden	of	OCD.	
Over	the	past	several	years,	research	has	investigated	the	DUI,	defined,	in	most	investigations,	as	the	
interval	between	the	onset	of	a	specific	psychiatric	disorder	and	the	administration	of	the	first	
pharmacological	treatment	at	standard	dosages	and	for	an	adequate	period	of	time,	in	adherent	
subjects	with	OCD	(Dell’Osso	and	Altamura,	2010).		
	
In	those	studies	taking	an	epidemiological	approach,	the	DUI	in	OCD	has	been	consistently	
demonstrated	to	count	among	the	longest	for	any	psychiatric	disorder	-	in	recent	years	ranging	between	
seven	and	ten	years	in	adults	(Altamura	et	al.,	2010;	Dell’Osso	et	al.,	2013b;	Poyraz	et	al.,	2015,	Albert	et	
al.,	2018a;	Benatti	et	al.,	2016),	and	exceeding	two	to	three	years	in	children	(Walitza	et	al.,	2008;	
Zellmann	et	al.,	2009).	These	estimates	are	alarming,	not	only	for	the	overall	duration	(in	the	case	of	
children,	constituting	almost	one	quarter	of	their	lifetime,	assuming	a	median	age	of	onset	of	11	years),	
but	also	because	in	adults	the	DUI	accounted	for	approximately	half	of	the	entire	duration	of	OCD.	This	
implies	that	patients	spent	half	of	their	illness	either	untreated	or	receiving	ineffective	treatment	
(Viswanath	et	al.,	2011;	Dell’Osso	et	al.,	2015,	Poyraz	et	al.,	2015).	Another	survey	of	child	and	
adolescent	referrals	to	a	centre	specialising	in	treating	therapy-resistant	OCD	found	that	fewer	than	half	
of	the	referred	patients	(44.8%)	had	received	adequate	first-line	treatment	with	CBT	or	SSRI	before	
receiving	care	from	this	tertiary	care	center	(Nair	et	al.,	2014).	Indeed,	young	people	appear	poor	at	
accessing	timely	treatment	and	'technical	treatment	failure'	represents	a	common	cause	of	apparent	
refractoriness	(Micali	et	al.,	2010).	Importantly,	the	DUI	in	children	and	adolescents	is	reported	to	
constitute	one	of	the	strongest	predictors	of	OCD	persistence	over	time	(Micali	et	al.,	2010).	
	A	number	of	factors	have	been	identified	as	contributing	to	the	high	DUI,	including	biological	(genetic	
loading),	familial/cultural	(stigma-related	attitudes),	psychological	(different	illness	phenotypes		and	
their	relationship	with	secretiveness		(Viswanath	et	al.,	2011,	Dell’Osso	et	al.,	2015,	Benatti	et	al.,	2016);	
believing	that	OCD	symptoms	do	not	represent	illness	(Poyraz	et	al.,	2015))	and	societal	factors	(poor	
access	to	psychiatric	services	with	expertise	in	the	diagnosis	and	management	of	OCD	(Menchon	et	al.,	
2016)).	A	recent	Italian	study	showed	a	progressive,	statistically	significant	reduction	of	the	latency	to	
first	pharmacological	treatment	emerging	across	subsequent	epochs	of	onset	in	patients	with	psychiatric	
disorders	including	OCD	(Dell’Osso	et	al.,	2016b).	In	other	words,	patients	with	a	more	recent	versus	a	
more	distant	onset	of	OCD	waited	less	time	before	receiving	a	guideline-recommended	treatment.	
Moreover,	the	shortening	of	the	DUI	was	related	to	improved	access	to	a	psychiatrist,	as	opposed	to	the	
GP	or	another	clinician,	implying	that	if	better	access	to	appropriate	clinical	services,	in	particular	to	a	
psychiatrist,	is	provided,	the	DUI	can	be	reduced.	
	
Specific	clinical	implications	have	been	linked	with	a	longer	DUI.	For	instance,	a	DUI	exceeding	24	
months	was	associated	with	a	poorer	response	to	pharmacological	treatment	(Dell’Osso	et	al.,	2010,	
Albert	et	al	2018a	(see	below)).	On	the	other	hand,	greater	severity	of	OCD	was	associated	with	a	
shorter	DUI	(Dell’Osso	et	al.,	2017),	probably	because,	as	has	been	demonstrated	elsewhere	(e.g.	
Fineberg	et	al.,	2013a),	those	who	are	more	severely	unwell	(and/or	their	caregivers)	are	more	likely	to	
seek	help	and	receive	treatment	sooner,	compared	with	those	with	a	more	chronic	but	fluctuant	form	of	
illness.		A	longer	DUI	may	also	be	associated	with	greater	family	accommodation	of	symptoms,	thereby	
counteracting	the	goals	of	exposure	and	response	prevention,	promoting	treatment	resistance	(Albert	
et	al.,	2017).	Moreover,	the	effect	of	accommodating	to	OCD	in	a	child	or	young	person	has	a	profoundly	
damaging	effect	on	family	relationships	and	the	health	of	family	members/caregivers	(Peris	et	al.,	2008).		
	
Another	negative	consequence	of	a	long	duration	of	untreated	OCD	is	the	development	of	a	greater	
burden	in	terms	of	associated	psychiatric	or	general	medical	conditions	(Aguglia	et	al.,	2018).	Persistent	
avoidance	of	medical	consultations	associated	with	untreated	fear	of	contamination,	for	example,	may	
lead	to	failure	to	achieve	appropriate	diagnosis	and	treatment	for	medical	problems	(Albert	et	al.,	2010),	
adding	further	burden	to	the	existing	psychiatric	disorder.	Anxiety	and	affective	disorders	are	found	to	
occur	in	over	60%	cases	(Ruscio	et	al.,	2010).	Psychiatric	comorbidity	is	associated	with	increased	
severity	and	chronicity	(Fineberg	et	al.,	2013b)	as	well	as	higher	levels	of	functional	impairment,	distress	
and	suicidality	(Angst	et	al.,	2005).	While	different	comorbid	disorders	impact	variously	on	distress	levels	
and	psychosocial	impairment,	largely	characterised	in	comorbid	OCD	by	damage	or	a	breakdown	in	close	
relationships,	bipolar	disorder,	unipolar	depression	and	alcohol	misuse	in	OCD	have	additionally	been	
associated	with	occupational	role	impairment	and/or	unemployment	(Fineberg	et	al.,2013b).	People	
with	OCD	and	OC	syndromes	are	also	more	likely	to	seek	treatment	if	they	suffer	with	a	comorbid	
psychiatric	disorder.		Severe,	chronic	illness	is	associated	with	high	direct	and	indirect	healthcare	costs	
and	high	levels	of	hospitalisation	(Drummond,	1993).	Around	25%	of	these	cases	attempt	suicide	
(Kamath	et	al.,	2007).		
	
The	epidemiological	and	clinical	correlates	of	the	DUI	in	OCD	are	of	particular	importance	in	the	context	
of	interventional	strategies	and	services.	DUI	represents	a	modifiable	factor,	and	intervention	programs	
aimed	at	promoting	early	diagnosis,	and	bridging	the	gap	between	child	and	adult	psychiatrists,	are	
likely	to	reduce	the	latency	to	effective	treatment	(Dell’Osso	et	al.,	2013c),	and	thereby	reduce	the	costs	
and	consequences	of	untreated	illness.	In	addition,	educative	public-health	programs	aimed	at	
promoting	early	OCD	diagnosis	should	be	disseminated	to	general	practitioners	and	consideration	given	
to	translating	scientific	knowledge	into	information	easily	available	for	the	general	population,	
increasing	the	recognition	of	OCD	by	the	lay	public	and	primary	care	clinicians.		
	
Early	Intervention	Targets	for	OCD	
Despite	 the	 availability	 of	 effective	 treatments	 for	 OCD	 (Hirschtritt	 et	 al.,	 2017),	 the	 treatment	 gap	
(difference	 between	 individuals	 with	 OCD	 needing	 treatment	 and	 those	 actually	 receiving	 it)	 was	
estimated,	 in	Europe,	 to	stand	at	25%	of	cases	 in	2004	(50%	approximately	 in	 the	world)	 (Kohn	et	al.,	
2004).	The	proportion	of	subjects	not	being	treated	worldwide	 in	more	recent	epidemiological	studies	
was	estimated	to	vary	between	22	and	92%,	with	38-to-90%	of	individuals	not	even	seeking	treatment	
or	advice	 (Garcia-Soriano	et	al.,	2014).	 	 In	 those	patients	with	OCD	receiving	 treatment,	 the	extended	
DUI	can	be	attributed	to	 long	delays	 in	actively	seeking	help	 (e.g.	 the	mean	 interval	between	disorder	
onset	and	help	 seeking	behavior	has	been	quantified	as	approximately	7	 years	 (Albert	et	 al.,	 2018a)).	
Educational	campaigns	presenting	OCD	as	an	illness	that	can	be	cured	and	resources	to	improve	access	
to	mental	health	services	could	in	the	near	future	shorten	the	delay	in	seeking	treatments.	
	
However,	 the	 interval	 between	 help	 seeking	 and	 receiving	 an	 adequate	 treatment	 for	 OCD	 is	 also	
significant	 (approximately	 2	 years	 for	 pharmacological	 treatment	 (Strengler	 et	 al.,	 2013;	 Albert	 et	 al.	
2018a)).	 This	 means	 that	 there	 is	 difficulty	 for	 physicians	 and/or	 mental	 health	 professionals	 in	
recognizing	and	diagnosing	OCD	appropriately	(high	rates	of	OCD	symptom	misidentification	by	mental	
health	 professionals	 were	 found	 (Glazier	 et	 al.,	 2013)),	 or	 in	 prescribing	 or	 offering	 an	 adequate	
treatment	 (it	 may	 be	 that	 psychological	 therapies	 other	 than	 CBT	 with	 exposure	 and	 response	
prevention	are	applied,	or	that	antidepressants	other	than	clomipramine	or	SSRIs	are	prescribed,	or	for	
less	 than	 the	 required	 12	weeks,	 or	 at	 sub-therapeutic	 doses).	 There	 is	 thus	 a	 strong	 need	 for	 early	
recognition	and	appropriate	diagnosis	for	OCD.	
	
The	 importance	of	shortening	the	DUI	becomes	evident	when	examining	treatment-response	rates.	 In	
patients	with	 OCD,	 response	 rates	 are	 significantly	 reduced	when	 the	 DUI	 is	 longer,	 and	 this	 is	 even	
more	evident	when	considering	the	first	ever	adequate	treatment	(e.g.	from	70%	to	40%	for	those	with	
a	DUI≤24	months	versus	>24	months)	(Dell’Osso	et	al.,	2010;	Albert	et	al.,	2018a).	This	may	imply	that	
the	longer	the	DUI	the	greater	the	“biological	or	psychosocial	damage”	associated	with	the	duration	of	
severe	 symptoms.	 It	 may	 be	 speculated	 that	 the	 DUI	 in	 OCD	 promotes	 neuroprogression	 or	
neurodegeneration,	 as	 hypothesized	 for	 psychosis	 (Anderson	 et	 al.,	 2014).	 Studies	 demonstrating	 an	
association	between	 longer	duration	of	OCD	and	either	 reduced	hippocampal	and	amygdalar	volumes	
(Atmaca	 et	 al.,	 2008)	 or	 reduced	N-acetyl	 aspartate	 among	 other	 neurochemical	measures	 in	 several	
cerebral	 areas	 (Gnanavel	 et	 al.,	 2014)	 provide	 some	 evidence	 in	 favor	 of	 a	 “neuroprogressive	 or	
neurodegenerative”	hypothesis.	Indeed,	an	as	yet	un-replicated	study	found	that	in	those	OCD	patients	
who	relapsed	after	discontinuation	of	drug,	response	rates	were	lower	following	re-instatement	of	the	
same	pharmacological	treatment	(same	compound	given	at	exactly	the	same	dosage)	compared	to	the	
initial	 response	 rates.	 	 These	 findings	have	been	 interpreted	 to	 suggest	 that	 relapse	 in	OCD	adversely	
affects	treatment	outcomes	(Maina	et	al.,	2001).	
	
Early	Intervention	for	Children	and	Adolescents	with	OCD		
It	would	seem	obvious	that	any	disorder,	including	OCD,	deserves	early	intervention	to	alleviate	
suffering	and	abbreviate	functional	impairments	associated	with	illness.	However	in	youth,	this	is	
particularly	crucial	due	to	several	specific	factors.		
	
First,	the	unique	cognitive,	academic	and	social	developmental	tasks	of	childhood	and	adolescence	are	
concentrated	into	a	relatively	few	years.	If	these	developmental	milestones	are	disrupted,	it	may	have	
lasting	consequences	well	beyond	childhood,	and	perhaps	even	a	lifelong	effect,	with	an	altered	
educational,	professional	or	social	trajectory.	Youth	are	therefore	particularly	vulnerable	to	the	effects	
of	mental	illness,	due	to	the	cascading	effects	of	functional	impairments	and	in	no	other	population	
does	early	intervention	hold	more	promise	for	reducing	chronicity,	and	the	economic	and	social	burdens	
associated	with	OCD.		In	addition,	children	are	frequently	less	able	to	articulate	their	obsessional	
thoughts	or	to	have	the	maturity	and	ego-function	to	recognize	their	obsessional	mental	experiences	as	
aberrant,	as	something	different	from	normal	self,	so	that	insight	may	be	lacking	and	obsessions	can	
only	be	inferred	by	(adult)	observers	of	ritualistic	behaviour	(Storch	et	al.,	2014).	
	
Next	are	the	illness-specific	factors	associated	with	OCD	in	youth	that	are	not	seen	as	frequently	in	
adults	and	that	may	require	specialist	knowledge	and	intervention.	These	include	symptom-specific	
presentations	or	symptom	dimensions	in	young	patients	(Geller	et	al.,	2001b,	Stewart	et	al.,	2007),	a	
unique	and	developmentally-specific	profile	of	common	comorbid	psychiatric	disorders	(Geller	et	al.,	
2001b),	a	unique	pattern	of	neurocognitive	deficits	(Geller	et	al.,	2017),	increased	familial	aggregation	of	
early-onset	OCD	(Rosario-Campos	et	al.,	2001,	Walitza	et	al.,	2010,	Taylor,	2011),	high	rates	of	family	
accommodation	as	a	consequence	of	children	being	embedded	in	family	units	and	perhaps	
environmental	or	epigenetic	influences	that	occur	at	a	sensitive	period	of	neural	maturation	(Geller	et	
al.,	2007).	Recently	it	was	shown	that	serotonin	transporter-	gene	methylation	levels	were	significantly	
higher	in	children	and	adolescents	with	OCD	compared	to	controls	and	adult	patients	with	OCD.	
Furthermore,	morning	awakening	salivary	cortisol	levels	positively	correlated	with	methylation	levels	
(Gruenblatt	et	al.,	2018).		Together,	these	findings	have	led	some	to	posit	a	developmental	subtype	of	
OCD	affecting	youth	and	this	is	partly	reflected	in	the	DSM-5	which	specifies	a	tic-related	form	of	OCD	
with	early	onset	that	is	male	predominant,	with	different	patterns	of	familial	inheritance,	comorbidity	
and	course	(American	Psychiatric	Publishing,	2013).	
	
Obsessional	anxiety	frequently	follows	developmental	themes	that	may	be	difficult	to	dissociate	from	
normal	childhood	development	(Geller	et	al.,	2000).	In	childhood,	evolving	autonomy	and	separation	
often	lead	to	fears	of	harm	to	attachment	figures	and	may	produce	behaviours	that	mimic	separation	
anxiety	but	are	driven	by	OCD	(Storch	et	al.,	2011),	while	in	adolescence,	tensions	around	sexuality	and	
moral	and	religious	development	frequently	find	their	way	into	obsessional	content	(Geller	et	al.,	2000).		
	
High	rates	of	psychiatric	comorbidity	also	present	clinical	challenges.	More	than	half	of	children	
diagnosed	with	OCD	will	meet	criteria	for	another	psychiatric	diagnosis,	even	in	epidemiological	
samples,	and	rates	as	high	as	80%	are	reported	in	clinically	ascertained	cohorts.	In	comorbid	OCD,	
medication	treatment	approaches	often	diverge,	producing	a	challenge	from	a	psychopharmacological	
perspective,	since	OCD	cannot	be	treated	in	isolation.	Each	comorbid	disorder	presents	risk	for	longer-
term	outcome	in	affected	children	(Walitza	et	al.,	2008).	Overlap	with	autism	spectrum	disorders	(ASD)	
is	common	and	can	present	diagnostic	and	treatment	challenges	particular	to	this	age	group	that	must	
necessarily	include	family	and	educational	interventions	(Volkmar	et	al.,	2014).	Clinical	studies	have	also	
demonstrated	comorbid	impulse-control	problems	such	as	tic	disorders	and	ADHD,	occurring	alongside	
anxiety	symptoms,	in	subsets	of	children	with	OCD,	co-segregating	in	families	and	often	presenting	a	
classical	“triad”	diagnostic	picture	(Geller	et	al.,	2007).	Impulse-control	problems	continue	to	feature	in	
cases	of	adult	OCD,	while	preclinical	research	has	identified	neuropsychological	markers	of	inhibitory	
dyscontrol	in	OCD	families	(Chamberlain	et	al.,	2005).	Prospective	studies,	beginning	in	childhood,	
investigating	the	role	of	latent	markers	of	the	association	between	early-onset	impulse-control	disorders	
and	OCD,	may	elucidate	a	specific	OCD	subtype	(Kessler	et	al.,	2011).	A	‘baby	sibs’	research	programme	
for	families	with	an	existing		child	with	OCD,	following-up	at	risk	siblings	from	birth	to	identify	early	signs	
and	biomarkers	indicating	a	role	for	early	intervention,	represents	a	rational	future	step.	
	
Finally,	treatment	approaches	and	outcomes	in	childhood	OCD	appear	to	be	somewhat	varied,	and	
possibly	more	optimistic,	compared	with	those	seen	in	adult	patients.	For	example,	family	therapy	
techniques	aimed	at	challenging	the	unhelpful	accommodation	of	OCD	symptoms	may	be	particularly	
helpful	in	the	younger	age	group	(Peris	et	al.,	2017).	In	a	meta-analysis	by	Stewart	and	colleagues	(2004)	
the	persistence	rate	for	full	OCD	was	around	40%	and	for	subthreshold	OCD	was	around	60%.	
Randomized	controlled	pharmacological	trials	have	been	hampered	by	very	high	placebo	response	rates	
in	children	(Geller	et	al.,	2003).	Compared	to	medication,	CBT	in	youth	has	undergone	less	controlled	
investigation	versus	psychological	placebo	(Skapinakis	et	al.,	2016),	but	is	acceptable	to	parents	and	
seems	particularly	effective	when	delivered	in	systematized	formats	that	include	family	participation	
(Peris	et	al	.,	2017).	Further,	the	recent	Nordic	long	term	treatment	study	(NordLOTS)	(Hojgaard	et	al.,	
2017)	suggests	that,	with	extended	CBT	protocols	tailored	to	outcome,	about	two	thirds	of	children	will	
have	good	outcomes	with	response	and	remission.	A	further	study	found	that	when		children	and	
adolescents	were	first	randomized	to	SSRI	or	group	CBT,	followed	by	a	second	randomization	to	switch	
or	add	the	other	treatment	for	non-responders,	significant	improvement	occurred	over	time	in	all	
groups,	regardless	of	the	sequence	of	treatments	(Fatori	et	al.,	2018).	
	
In	summary,	youth	with	OCD	present	particular	challenges	but	also	a	hopeful	outcome	picture	when	
early	intervention	can	be	applied	in	standardized	way	that	can	mitigate	the	prolonged	harmful	effects	of	
untreated	illness	(Storch	et	al.,	2018).	No	prospective	controlled	longitudinal	study	has	examined	
whether	effective	early	intervention	reduces	long-term	disability	from	OCD	(or	impact	on	a	child’s	ability	
to	meet	developmental	milestones). Although	the	question	as	to	whether	or	not	early	intervention	
produces	better	outcomes	ideally	requires	testing	in	a		prospective	randomised	controlled	trial,		it	is	
unlikely,	for	ethical	reasons,	that	a	study	requiring	adequate	treatment	to	be	withheld	would	ever	be	
undertaken.	Nevertheless,	we	judge	many	of	the	arguments	supporting	early	intervention	for	OCD	in	
childhood	(alleviating	suffering,	optimising	the	navigation	of	critical	developmental	milestones,	
counteracting	negative	effects	of	family	accommodation,	better	treatment	outcomes	compared	to	
adulthood	OCD)		to	be		strong	and	strategies	for	early	intervention	should	be	incorporated	into	existing	
standards	of	care	programmes	(such	as	Menchon	et	al.,	2016).		
	
Staging	models	for	OCD	
“Illness	staging”	is	a	commonly	used	technique	in	several	medical	disciplines,	helping	to	predict	course	
or	prognosis	and	optimize	treatment	(Berk	et	al.,	2017).		Staging	models	in	psychiatry	have	mainly	been	
applied	to	schizophrenia,	bipolar	disorder	and	depression	(de	la	Fuente-Tomas	et	al.,	2018).	Based	on	
the	proposition	that	psychopathology	advances	predictably,	they	propose	an	“at-risk”	or	latency	stage,	a	
prodromal	stage	with	the	odds	of	progressing	to	a	first	clinical	threshold	episode,	and	a	full	illness	stage	
with	the	potential	to	revert	or	progress	to	late	or	end-stage	manifestations.		Such	models	imply	the	
presence	of	an	active	disease	process	that,	if	not	remediated,	leads	to	neuro-progression,	a	more	
damaging	disease	course	and	functional	deterioration	(Berk	et	al.,	2017).	Staging	models	also	imply	that	
stage-specific	treatments	may	be	successful	in	impeding	illness	progression	as	well	as	targeting	
symptom	reduction.	These	treatment	approaches	range	from	‘prevention’	for	at-risk	individuals,	to	early	
intervention	approaches	for	prodromal	and	newly	diagnosed	individuals,	complex	combination	therapy	
for	recurrent	or	resistant	illness,	and	palliative-type	approaches	for	those	with	chronic,	late	stages	of	
illness	(Berk	et	al.,	2017).		
	
A	similar	staging	model	could	be	proposed	for	OCD	and	other	OCRDS.	The	utility	and	validity	of	such	a	
model	would	depend	on	evidence	linking	the	different	stages	to	clinical	outcome,	treatment	response	
and	neurobiological	measures.		A	substantial	proportion	of	the	population	(estimated	at	21%	and	28%	in	
the	studies	by	Ruscio	et	al.,	2010	and	Fineberg	et	al.,	2013a)	report	subthreshold	symptoms	that	may		
represent	the	first	‘at	risk’	stage.	These	individuals	do	not	meet	the	full	diagnostic	criteria	for	OCD,	and	
in	the	main	do	not	progress	to	full	blown	OCD,	but	do	nevertheless	experience	some	harms	(Fullana	et	
al.,	2009,	Fineberg	et	al	2013a).	Conversely,	cases	of	full-blown	OCD	are	usually	preceded	(or	followed	
by)	sub-diagnostic	OC-symptoms	(Fineberg	et	al.,	2013a).	One	study	indicated	that	the	earliest	
symptoms	shown	by	OCD	patients	belong	to	the	symmetry	and	ordering	dimension	(Kichuk	et	al.,	
2013).These	symptoms	may	be	of	particular	relevance	for	identifying	those	most	at	risk	of	developing	
OCD.	Appropriate	methods	of	clinical	intervention	for	these	cases	remain	a	matter	for	further	research,	
as	traditional	treatments	(including	SSRI,	CBT)	may	not	be	appropriate.	In	the	case	of	at	risk	children,	as	
a	general	principle,	it	would	seem	wise	to	educate	parents	not	to	accommodate	OC	symptoms	and	how	
to	avoid	undue	antagonism.			
	As	described	above,	OCD	develops	in	vulnerable	cases,	including	those	with	prodromal	OC	symptoms,	
through	the	actions	and	interactions	of	specific	inherited	and	environmental	risk	factors,	such	as	family	
history	of	OCD,	tic,	or	exposure	to	trauma	or,	in	the	case	of	young	women,	pregnancy	and	childbirth.	
Individuals	with	subthreshold	OC	symptoms	or	traits	(especially	symmetry,	ordering)	alongside	exposure	
to	these	factors	may	therefore	represent	the	second	stage	i.e.	“ultra-high	risk’	mental	states,	for	whom	
early	intervention	in	the	form	of	careful	monitoring	to	prevent	progression	to	full	blown	OCD	would	be	
relevant.	There	are	thus	arguments	to	actively	screen	for	OC	symptoms	and	syndromes	in	appropriate	
high	risk	groups,	such	as	within	maternity	services,	focussing	on	ultra-high	risk	parents	and	children.		
	
OCD	represents	the	next	stage,	manifesting	usually	in	childhood	as	the	first	clinical	episode	and	
requiring	intervention	with	evidence	based	treatments	such	as	CBT	and	SSRI.	Further	stages	of	illness	
could	be	conceptualised	as	responsiveness	or	resistance	to	different	interventions	(CBT,	SSRI,	
antipsychotic)	staged	according	to	evidence	–	based	algorithms	(e.g.	Fineberg	et	al.,	2015).	
	
The	establishment	of	a	staging	model	would	generate	testable	hypotheses	for	onwards	validation	in	
longitudinal	naturalistic	trials,	addressing	gaps	in	knowledge	e.g.	the	proportion	of	cases	staged	as	
medium	or	high	risk	eventually	developing	OCD	and	the	predisposing	or	precipitating	factors	linked	to	
transition	to	the	full	disorder,	as	well	as	interventional	studies	e.g.	the	effectiveness	of	low	intensity	CBT	
interventions	in	sub-syndromal	groups	in	relieving	distress	or	preventing	conversion	into	OCD.		
	
Immunological	Factors	and	Early	Intervention	
The	role	of	the	immune	system	and	inflammation	in	OCD	pathophysiology	emerged	in	the	early	nineties,	
when	an	autoimmune	pathophysiology	hypothesis	was	proposed	for	several	case	series	of	OCD	
characterized	by	pre-pubertal	acute	onset,	episodic	course	and	concurrent	neurological	abnormalities	
such	as	choreiform	movements	occurring	or	exacerbating	after	exposure	to	infection	(Swedo	et	al.,	
1998).	This	syndrome,	initially	termed	pediatric	autoimmune	neuropsychiatric	disorder	associated	with	
group	A	beta-hemolytic	streptococcus	(GABHS)	(PANDAS),	was	renamed	pediatric	acute	
neuropsychiatric	syndrome	(PANS),	since	evidence	highlighted	the	fact	that	several	agents	other	than	
streptococcus	might	be	involved	(Chiarello	et	al.,	2017).	The	mechanism	hypothesized	for	PANS	involves	
cross-reactivity	between	gangliosides	in	basal	ganglia	neurons	with	the	GABHS	and/or	other	agents’	
cells,	as	is	the	case	for	the	Sydenham’s	chorea	(Chiarello	et	al.,	2017).	Indeed,	there	are	some	reports	of	
anti-basal	ganglia	antibodies	in	the	serum	of	PANDAS/PANS	cases	(Pearlman	et	al.,	2014).	Also,	evidence	
of	inflammatory	and	immune	system	abnormalities	in	the	form	of	higher	rates	of	total	monocytes	and	
CD16+	monocytes	were	reported	in	pediatric	OCD	(Rodríguez	et	al.,	2017).		
	
Inflammatory	biomarkers	are	important,	as	they	may	identify	a	potentially	remediable	prodromal	stage	
of	early	onset	OCD.	The	relevance	of	neuro-inflammation	and/or	autoimmunity	in	OCD	is	not	necessarily	
limited	to	subsets	of	pediatric	and	acute	onset	forms	of	OCD,	and	could	be	also	relevant	for	adults.	
Indeed,	recent	studies	showed	the	presence	of	inflammation	in	the	cortico-striatal-thalamo-cortical	
circuit	(Attwells	et	al.,	2017)	and	the	presence	of	greater	plasma	levels	of	IL-2,	IL-4,	IL-6,	IL-10	and	TNF-α	
levels	in	adult	OCD	patients	compared	to	controls	(Rao	et	al.,	2015),	as	well	as	higher	rates	of	anti-basal	
ganglia	antibodies	(Pearlman	et	al.,	2014,	Nicholson	et	al.,	2012).	Systemic	autoimmune	diseases	are	
reported	to	be	associated	with	an	increased	risk	of	OCD	(Wang	et	al.,	2018).	Other	recent	evidence	
showed	that	the	gut-microbiota	may	have	a	potential	role	in	brain	inflammation	and	PANDAS/PANS	
cases	(Quagliarello	et	al.,	2018).	Thus,	neuro-inflammation	and	autoimmunity	seems	to	be	involved	in	
several	forms	of	OCD,	perhaps	especially	OCD	related	to	tic	or	movement	disorders	(Orefici	et	al.,	2016).	
An	ongoing	European	longitudinal	observational	multicenter	study	is	investigating	the	association	of	
environmental	(e.g.	infectious	agents)	factors	with	the	onset	and	course	of	tics	and/or	OC	symptoms	
through	the	prospective	observation	of	at-risk	individuals	(Schrag	et	al.,	2018).	Finally,	a	recent	genome-
wide	association	study	found	genetic	correlations	between	immune-related	disorders	and	several	
psychiatric	disorders,	including	OCD	(Tylee	et	al.,	2018).	
	
Although	some	studies	demonstrated	that	OCD	symptoms	have	improved	with	plasma	exchange,	
intravenous	immunoglobulin	and	antibiotic	prophylaxis	(e.g.		Snider	et	al.,	2005),	the	use	of	antibiotics	
and	immunoglobulins	for	early	and	acute	onset	OCD	patients	remains	controversial	(Burchi	and	Pallanti,	
2018;	Williams	et	al.,	2016).Additional	evidence	hints	at	a	potential	therapeutic	role	for	anti-
inflammatory	agents	(Spartz	et	al.,	2017).	Interestingly,	SSRIs	(a	first	line	OCD	treatment)	have	been	
shown	to	exert	several	immunological	effects,	such	as	reduced	lymphocyte	proliferation,	alteration	of	
cytokine	secretion	and	induction	of	apoptosis	(Gobin	et	al.,	2014).		
	
	
Therefore,	when	treating	a	patient	presenting	with	early	onset	OCRD,	clinicians	should	consider	an	
assessment	of	inflammatory	and	immunological	aspects,	such	as	infective	history,	OCD	symptom-course,	
inflammatory	markers,	familial	history	of	autoimmunity	and	the	gut-microbiota.	Early	recognition	of	
inflammatory	and	immunological	factors	in	early	and	acute	onset	OCD	patients	may	represent	a	crucial	
starting	point	for	appropriate	intervention	in	this	population	and	could	potentially	advance	the	field	
toward	a	putative	etiological	treatment	of	OCD.		
	
	
Monitoring	and	Early	Prevention	Via	Remote	Digital	Assessment		
The	extensive	use	of	smartphones	and	vast	amount	of	information	they	contain,	has	positioned	cellular	
devices	and	technology	as	a	rich	database	for	behavioural	and	social	activities	(World	Health	
Organization	Report	(2011)).	Harnessing	smartphone	technology	into	the	clinical	field	has	introduced	
new,	real	time,	data	sources	that	hold	promise	in	characterizing	clinical	functioning	(The	National	
Institute	of	Mental	Health	(2017)).	Characterizing	clinical	populations	based	on	such	data	sources,	
known	as	digital	phenotyping,	is	a	new	way	of		identifying	individuals	at	risk,	appropriately	deploying	
interventions,	and	assessing	their	efficacy	(Faurholt-Jepsen	et	al	.,	2017).	
	
Clinical	disorders	characterized	by	heightened	compulsivity	(e.g.	OCD	,	body	dysmorphic	disorder,	
gambling	disorder,	restricting	anorexia	nervosa),	represent	disorders	for	which	the	human-device	
interface	can	putatively	represent	a	significant	area	of	observed	symptomatology.	Applications	like	
‘Instagram’	have	issued	health	support	platforms	for	their	users,	in	response	to	acknowledging	that	
mental	health	symptoms	are	linked	with	the	use	of	its	platform.	PUI-related	symptoms	are	prevalent	in	
specific	age	groups	of	individuals	with	OCD	(Ioannidis	et	al.,	2018).	While	the	concept	of	PUI	is	still	under	
debate,	and	the	direction	of	causation	of	the	observed	correlations	is	still	contentious,	there	is	
anecdotal	evidence	that	the	online	platforms	facilitate	a	‘millieu’	in	which	OCD	symptoms	flourish	
(Mazmanian	et	al.,	2017).		
	Digital	monitoring	is	most	relevant	in	groups	for	whom	there	is	a	high	risk	of	delayed	or	missed	
diagnosis,	where	health	services	compliance	is	low	and	symptoms	are	often	concealed,	such	as	
adolescents	and	young	adults.	Therefore,	there	is	an	argument	for	the	use	of	digital	phenotyping,	
created	using	an	anonymous	monitoring	app,	downloaded	by	those	in	high	risk	groups.	The	resulting	
data	would	enrich	clinical	monitoring	with	an	objective	and	continuous	data	source.	Therefore,	data	
mining	methods	are	highly	relevant	for	the	early	detection	and	diagnoses	of	OCRD,	where	compulsions	
may	be	performed	using	the	human-device	interface	(online	checking,	taking	photos,	list	making	etc.)	
and	can	provide	a	unique	digital	signature,	which	can	be	statistically	characterized.	This	may	open	a	
wide	array	of	novel	screening	methods	and	digital	instruments,	which	can	boost	early	detection	of	
OCRDs.	Although	self-report	of	OCRD	symptoms	has	a	generally	acceptable	reliability,	such	methods,	
have	the	propensity	to	source	high	dimensional	24h	longitudinal	data	and	enable	the	detection	of	covert	
symptoms	which	are	otherwise	hard	to	subjectively	or	objectively	monitor,	due	to	their	nature	(e.g.	
complex	diurnal	variation).	Thus,	several	clinical	situations	characterizing	OCRD	could	be	better	
understood,	and	possibly	prevented,	by	employing	a	digital	personalized	model	capable	of	predicting	
when	certain	deviations	from	a	patient’s	usual	behavior	may	lead,	with	high	probability,	to	his	or	her	
health	deterioration,	or	indicate	that	a	deterioration	has	already	occurred.		
	
During	this	informatics	age,	it	is	highly	important	that	personal	information	is	handled	sensitively	and	
the	right	to	private	life	is	respected	in	the	digital	space.	Therefore,	it	is	essential	to	highlight	that	a	
collection	of	personalized	data	of	such	nature,	should	be	managed	through	rigorous	processes	and	via	
secure	mediums	and	databases,	for	which	participants	have	given	explicit	consent.	Researchers	and	
clinicians	setting	up	such	processes	would	undertake	this	endeavour	with	grave	ethical	sincerity.	Data	
collection	of	such	magnitude	and	sensitivity	would	be	acceptable,	if	it	was	completely	anonymous.	As	
such,	techniques	can	be	implemented	by	which	devices	could	allow	the	sourcing	of	passive	data	sources	
(communication	and	diurnal	variation	patterns,	social	media	and	internet	use,	gyroscope	movement,	
app	usage,	location	information,	word	use	and	keyboard	use),	along	with	anonymous	active	data	
sources	(voice	prosody,	facial	and	eye	coding,	linguistic	analysis,	remote	survey).	Computational	
approaches	in	machine	learning	(e.g.	data	mining)	and	artificial	intelligence	may	then	be	used	to	derive	
clinical	characterization	and	prediction	based	on	these	sources	of	big	data,	creating	clinically	valid	
screening	and	monitoring	algorithms,	which	could	be	applied	for	early	detection	and	intervention	in	high	
risk	populations.			
	
Toward	Primary,	Secondary	and	Tertiary	Prevention?	
In	considering	the	development	of	early	intervention	strategies,	it	can	be	useful	to	conceptualise	the	
‘prevention’	of	OCD	and	OCRDs	in	terms	of	primary,	secondary	and	tertiary	prevention.	Primary	
prevention	involves	the	prevention	of	the	development	of	OC	symptoms.	Secondary	prevention	refers	
to	the	early	identification	and	treatment	of	individuals	who	develop	OC	symptoms	to	prevent	
progression	to	OCRDs.	Evidence	shows	that	patients	continue	to	improve	over	time	and	those	who	stay	
longer	under	treatment	tend	to	benefit	more	from	it.	Therefore,	the	earlier	the	patient	starts	getting	
treated,	the	more	likely	he/she	will	stay	under	treatment	long	enough	to	improve	(Costa	et	al.,	2017,	
Jakubovski	et	al.,	2012,	Diniz	et	al.,	2011).	Tertiary	prevention	aims	to	reduce	the	impact	of	the	disorder	
and	the	level	of	disability	once	individuals	have	been	diagnosed.	However,	the	literature	in	relation	to	
the	prevention	of	OCRDs	is	sparse.	
	
A	combination	of	genetic	and	environmental	factors	appear	to	be	relevant	to	the	aetiology	of	OCD,	e.g.	
the	observation	that	hoarding	symptoms	and	contamination/cleaning	symptoms	are	more	likely	to	also	
be	present	in	first-degree	relatives	(Brakoulias	et	al.,	2016b, Zilhão		et	al.,	2018).	These	factors	are	
thought	to	interact	to	precipitate	OCD	in	individuals	with	subthreshold	symptoms.	Thus	the	primary	
prevention	of	OCD	could	involve	strategies	to	prevent	the	genetic	expression	of	OCD	or	modifying	
environmental	factors	that	might	contribute	to	the	expression	of	OCD.	As	genetic	strategies	have	not	yet	
advanced	to	a	stage	of	being	used	therapeutically	(see	above),	we	must	currently	look	towards	
environmental	factors.	For	80%	of	people	with	OCD,	their	symptoms	begins	in	childhood	(Goodman	et	
al.,	1995),	with	the	first	peak	of	onset	being	reported	around	11	years	of	age	(Taylor,	2011).	Early-life	
factors,	including	physical	abuse,	negative	emotionality,	perinatal	insults,	poor	motor-development	and	
personality	or	conduct	problems	have	been	reported	to	predict	the	incidence	of	OCD	(Grisham	et	al.,	
2011).	Hence	childhood	environmental	factors	are	a	target	area	of	investigation.		
	
Psychoeducation	and	the	reduction	of	family	accommodation,	i.e.	the	act	of	parents,	siblings	or	partners	
accommodating	to	the	high-risk	individual’s	requests	to	comply	with	their	compulsions,	are	promising	
areas	for	primary	prevention,	but	have	only	been	evaluated	as	secondary	preventative	measures	with	
some	evidence	that	CBT-based	family	intervention	programmes	improve	treatment	outcomes	(Merlo	et	
al.,	2009).	Thus,	currently	the	impact	of	such	programmes	on	the	long	term	prognosis	is	unknown.	
	
,	The	advantages	of	anticipating	treatment	initiation	through	early	intervention,	so	that	patients	can	
benefit	from	long-term	improvement	with	treatment	maintenance,	requires	evaluation	in	long	term	
studies.	Nevertheless,		it	can	be	postulated	that	early	intervention	in	childhood	provides	an	opportunity	
to	reduce	symptoms	and	their	impact	on	a	child’s	ability	to	meet	developmental	milestones	(Freeman	et	
al.,	2007).The	hypothesis	that	some	OCRDs	may	be	precipitated	by	neuro-immunological	reactions	has	
spurred	several	treatment	studies.	Although	the	generalisability	of	immune	modulating	interventions	
remains	unclear,	if	OC	symptoms	are	detected	early,	such	treatments	could	be	viewed	as	secondary	
prevention	or	early	intervention.	Biomarkers	that	might	predict	who	will	respond	to	these	often	costly	
and	limited	treatments	are	also	required.	
	
Tertiary	prevention	has	been	limited	by	an	inadequate	number	of	trained	clinicians	to	deliver	evidence	
based	treatments	such	as	exposure	and	response	prevention	therapy	(Brakoulias	et	al.,	2016a).	Tertiary	
prevention	would	also	aim	to	reduce	the	significant	comorbidity	associated	with	OCD	with	
approximately	75%	having	a	co-occurring	other	anxiety	disorder	(Brakoulias	et	al.,	2011)	and	higher	
rates	of	ADHD,	tic	disorders,	major	depression	(Hasler	et	al.,	2007)	and	suicide	(Alonso	et	al.,	2010,	
Maina	et	al.,	2007,	Kamath	et	al.,	2007).	Indeed,	OCD	was	one	of	the	most	important	predictors	of	
lifetime	comorbidity	in	the	World	Mental	Health	Surveys	and,	as	an	early-onset	disorder,	represents	an	
important	marker	of	youth	at	high	risk	for	progression	to	later	disorders	(Kessler	et	al.,	2011).	The	wider	
dissemination	of	clinical	practice	guidelines	promoting	evidence-based	treatments	(e.g.	National	
Institute	for	Health	and	Clinical	Excellence	2006,	Menchon	et	al.,	2017)	could	be	seen	to	assist	tertiary	
prevention.	
	
Early	intervention	in	low	and	middle	income	countries		
The	importance	of	developing	early	intervention	programs	for	mental	health	problems	in	low	and	
middle	and	low-income	countries	(LMIC)	is	obvious.	First	and	foremost,	as	the	majority	of	the	world	
population	resides	in	LMIC,	most	individuals	with	or	“at	risk”	for	OCRDs	live	in	these	regions.	Secondly,	
most	of	the	research	on	both	OCRDs	and	early	intervention	has	been	performed	in	high-income	
countries	(HIC),	thus	excluding	individuals	with	different	ethnic	and	sociocultural	backgrounds	(Durkin	et	
al.,	2015).	It	is	therefore	unclear	how	data	from	HIC	samples	apply	to	subjects	from	LMIC.	Finally,	the	
amount	of	resources	that	can	be	dedicated	to	early	intervention	for	mental	health	problems	(including	
OCRDs)	is	both	lower	than	those	from	HIC	and	more	likely	to	be	affected	by	problems	such	as	political	
instability,	economic	crisis,	or	even	war,	among	others	(Parra-Cardona	et	al.,	2018).	However,	the	
concept	of	LMIC	is	also	heterogeneous.	For	instance,	countries	with	stronger	economies,	such	as	Brazil,	
Russia,	India,	China,	and	South	Africa	(collectively	known	as	the	BRICS)	were	able	to	establish	an	early	
intervention	program	for	psychosis	and	to	perform	relevant	research	in	OCRDs	(e.g.	Reddy	et	al.,	2010).	
It	is	natural	for	them,	therefore,	to	turn	their	attention	to	early	intervention	for	OCRDs.	
	
There	is	now	evidence	from	studies	performed	in	some	LMIC	that	DUI	in	OCD	is	similar	to	those	in	other	
parts	of	the	world	(Poyraz	et	al.,	2015).	For	instance,	a	recent	Brazilian	study	found	that	the	mean	DUI,	
calculated	as	the	age	at	which	patients	were	first	seen	by	a	mental	health	professional	minus	the	age	at	
onset	of	OCD,	was	almost	eight	years	(Vigne	et	al.,	2018).	However,	DUI	in	OCD	may	be	shortened	by	
other	targeted	enterprises.	In	2003,	seven	Brazilian	universities	established	The	Brazilian	Research	
Consortium	for	Obsessive-Compulsive	Spectrum	Disorders	to	strengthen	and	develop	research	on	
OCRDs	across	the	country	(Miguel	et	al.,	2008).This	initiative	was	made	possible	by	significant	
investments	of	the	Brazilian	research	funding	agencies,	which	allowed	training	in	OCRDs’	assessments	
across	different	centres,	and	also	by	the	structure	of	the	Brazilian	health	system	itself,	which	is	
universal,	comprehensive,	decentralised,	and	free	of	charge	in	terms	of	service	provision.	These	
initiatives	helped	to	establish	Brazil	as	one	of	the	research	hubs	in	OCRDs	and	also	to	leverage	
assessment	and	treatment	of	OCRD	across	the	country.		
	In	this	specific	context,	attempts	to	shorten	DUI	in	OCRDs	should	probably	involve	greater	contact	
between	local	mental	health	specialists	and	family	physicians,	one	of	the	tenets	of	the	Brazilian	mental	
health	system	(Fagundes	Junioret	al.,	2016).	Nevertheless,	if	we	consider	the	DUI	as	the	delay	between	
the	awareness	of	the	discomfort	or	interference	in	functioning	caused	by	OCD	symptoms	-	instead	of	
OCD	symptoms	onset	-	and	the	initiation	of	OCD-specific	treatment,	the	mean	DUI	is	still	substantially	
high	(Miguel	et	al.,	2008).	Therefore,	even	in	the	context	of	universal	access	to	public	health	services	in	
LMIC	such	as	Brazil,	there	is	a	significant	delay	to	OCD-specific	treatment	initiation	explained	by	factors	
that	go	beyond	treatment	availability.	
	
Integration		
OCD	has	a	profound	impact	on	the	quality	of	life	of	the	subject	and	involves	a	significant	burden	on	the	
individual,	the	family	and	society.	The	consequences	of	OCD	may	be	increased	by	the	frequently	
associated	comorbidities,	such	as	depression	or	anxiety	disorders.	Individuals	suffering	with	OCD	that	
has	either	not	been	detected	or	not	properly	treated	are	likely	to	experience	these	consequences.	The	
recognition	that	OCD	occurs	within	an	expanded	diagnostic	class	of	OCRDs,	with	a	combined	prevalence	
estimated	at	9.1%	(OCD	+	OCD	related	disease	prevalence)	(Carmi	et	al.,	2019),	implies	that	OCD	and	
OCRD	are	affecting	roughly	one	out	of	11	of	the	general	population.		
	
OCD	frequently	emerges	in	childhood	and	adolescence,	and	through	the	burden	(which	evolves)	of	the	
time	and	energy	spent	on	the	OCD,	has	the	potential	to	(and	often	does)	interfere	with	the	achievement	
of	social	and	occupational	milestones.	These	secondary	phenomena	(lacking	social	occupational	and	
interpersonal	skills)	add	another	degree	of	difficulty	and	resistance	to	treatment	that	could	have	been	
averted,	had	treatment	started	earlier.	The	same	is	true	for	secondary	depression,	which	is	common	and	
very	frequently	presents	another	hurdle	on	the	road	to	recovery		
	
The	issue	of	DUI	in	OCD	is	different	from	other	severe	brain	disorders,	as	it	is	quite	likely	that	for	many	
individuals	there	is	the	possibility	to	disguise	the	symptoms	from	family	and	friends	for	some	
considerable	time.	The	ego	–	dystonic	features	(symptoms	accepted	as	integral	to	the	individual’s	values	
and	goals)	and	poor	insight	(unawaress	that	the	obsession	and	/	or	compulsion	is	excessive	or	
unreasonable)	frequently	seen	in	OCD	may	also	deter	individuals	from	coming	forward.	Moreover,	as	
the	symptoms	are	frequently	territorial	and	narrowly	focused	(as	opposed	to	depression,	psychosis	etc.),	
OCD	is	more	likely	to	escalate	under	the	“clinical	radar”	and	consequently	exerts	an	even	bigger	
(unwanted)	effect,	not	only	on	quality	of	life	but	also	on	psycho-social	functioning.		
	
Due	to	the	specific	characteristics	of	OCD	(ego-dystonic	and	territoriality)	on	the	one	hand	and	the	
tendency	of	the	disorder	to	get	worse	over	time	(as	opposed	to	the	usually	episodic	course	of	MDD	for	
example),	OCD	and	OCRDs	are	conditions	for	which	early	detection	is	both	challenging	and	critical.	
Another	relevant	point	relates	to	the	known	“toxic	effects”	of	the	illness;	longer	duration	is	not	only	
associated	with	increase	in	severity	and	burden,	but	also	interfaces	with	other	domains	ranging	from	
occupation	to	social	life,	parenting	and	personal	relationship.	As	the	impact	on	the	quality	of	life	
worsens	with	the	passage	of	time,	the	relevance	and	importance	of	early	detection	and	intervention	for	
these	disorders	appears	obvious.	
	
We	therefore	recommend	adoption	and	validation	of	a	staging	model	for	OCD,	linked	to	primary,	
secondary,	tertiary	prevention,	focussing	on	addressing	environmental	and	biological	etiological	targets.	
As	we	do	not	as	yet	have	evidence	that,	by	addressing	modifiable	environmental	risk	factors	such	as	
parental	rearing	practices,	the	primary	prevention	of	full-blown	OCD	in	individuals	thought	to	be	at	risk	
is	possible,	early	intervention	is	likely	to	be	of	greater	importance	for	clinicians	and	health	services.	This	
model	has	scope	for	application	at	a	global	level,	including	among	LMIC.		Moreover,	recent	advances	in	
information	technology	have	the	capacity	to	transform	the	way	we	approach	early	intervention	and	
change	the	landscape	in	this	regard.		
	
The	emphasis	on	early	detection	rests	upon	the	known	clinical	and	cost	effectiveness	of	currently	
available	interventions	(SRIs,	ERP,	family	interventions)(	National	Institute	for	Health	and	Clinical	
Excellence	2006).	By	applying	these	treatments	early,	there	is	a	real	possibility	of	altering	(positively)	the	
trajectory	of	OCD	and	OCRD,	to	enable	patients	to	free	themselves	from	the	prison	of	their	symptoms	
and	access	the	opportunity	to	fulfill	their	potential.	This	component	i.e.	the	availability	of	effective	
therapeutic	tools,	gives	early	intervention	for	OCD	clinical	weight.	“Had	we	done	it,	it	would	really	have	
had	significant	clinical	impact”.		
	
Thus,	early	detection	and	intervention	strategies	could	be	expected	to	prevent	chronic	evolution,	are	
likely	to	be	cost-effective	and	to	improve	the	quality	of	life	and	reduce	the	overall	burden	of	illness.	
Achievable	objectives	include	reliable	identification	of	‘at	risk’	and	established	cases	of	OCD	e.g.	based	
on	family	history,	phenotype	and	significant	life	events	such	as	pregnancy	and	childbirth,	alongside	
timely	diagnosis	and	improved	access	to	clinicians	and	services	capable	of	providing	targeted	
interventions,	with	the	explicit	aim	of	reducing	the	DUI	and	consequently	the	treatment	gap	and	its	
damaging	effects	on	mental	wellbeing.		As	OCD	is	an	illness	with	its	onset	in	childhood	and	early	to	
middle	adulthood,	there	are	strong	arguments	for	targeting	such	interventions	in	child	and	adolescent	
mental	health	services,	services	covering	the	‘transitional’	phase	between	childhood	and	adulthood	and	
maternity	services.		
	
As	many	at	risk	individuals	will	not	turn	out	to	develop	OCD,	and	we	do	not	as	yet	have	reliable	outcome	
predictors	to	determine	who	will,	it	is	proper	to	consider	the	potential	harms	of	early	intervention	in	the	
prodromal	stages.	For	example,	undue	emphasis	may	be	placed	on	dysfunctional	behaviours	that	
spontaneously	remit.	These	‘false	positive’	findings	may	cause	unnecessary	anxiety	or	distress,	especially	
for	parents	of	at	risk	children,	and	may	even	lead	to	unnecessary	interventions	in	some	cases.	These	
harms	are	not	specific	to	OCD,	relating	to	early	interventions	for	many	other	conditions	associated	with	
a	disease	burden,	and	need	to	be	balanced	against	known	harms	related	to	missing	the	diagnosis.	Based	
on	evidence	presented	in	this	review,	we	believe	that	careful	monitoring	of	ultra-high	risk	cases	of	OCD	
is	reasonable,	not	only	because	of	the	increased	risk	of	developing	OCD,	but	also	because	cases	with	a	
family	history	of	OCD	may	have	a	six	times	lower	response	to	CBT	(Garcia	et	al.,	2010)	and	so	need	to	be	
identified	early	and	treated	appropriately.	We	would	therefore	argue	that	an	early	intervention	model	
for	OCD,	with	the	level	of	intervention	matched	to	the	stage	of	illness,	aligns	with	the	precautionary	
principle	guiding	public	health	organizations’	recommendations	and	actions,	requiring	that	"…	scientific	
uncertainty	should	not	be	used	as	a	reason	to	postpone	preventive	measures"	(World	Health	
Organization,	2018).		
	
Limitations	
This	consensus	statement	is	not	a	systematic		review.	Systematic	reviews	come	with	their	own	
weaknesses	e.g.	bias	driven	by	the	selection	of	search	strategy	chosen	by	the	authors,	and	therefore	do	
not	represent	a	flawless	process.	We	believe	a	narrative	review	is	best	suited	for	the	purpose	of	such	
newly	explored	ground.		We	acknowledge	there	is	as	yet	little	or	no	prospective	evidence	that	early	
intervention	will	actually	result	in	better	outcomes.	Nevertheless	,	the	consensus	opinion	of	this	global	
group	of	experts,	derived	from	this	narrative	review,	is	that	early	intervention	based	on	validated	
staging	models,	yet	to	be	fully	defined,	represents	the	way	forward.		
	
	
	
	
	
	
	
	
	
	
	
	
References	
Aguglia,	A.,	Signorelli,	M.S.,	Albert,	U.,	Maina,	G.,	2018.The	Impact	of	General	Medical	Conditions	in	
Obsessive-Compulsive	Disorder.	Psychiatry	Investig.	15(3),	246-253.	
Albert,	U.,	Bogetto,	F.,	Maina,	G.,	Saracco,	P.,	Brunatto,	C.,	Mataix-Cols,	D.,	2010.	Family	accommodation	
in	obsessive-compulsive	disorder:	Relation	to	symptom	dimensions,	clinical	and	family	characteristics.	
Psychiatry	Res.179(2),204-11.	
Albert,	U.,	Baffa,	A.,	Maina,	G.,	2017.	Family	accommodation	in	adult	obsessive-compulsive	disorder:	
clinical	perspectives.	Psychol	Res	Behav	Manag.	10,	293-304.		
Albert,	U.,	Barbaro,	F.,	Bramante,	S.,	Rosso,	G.,	De	Ronchi,	D.,	Maina	G.,	2018a.	Duration	of	untreated	
illness	and	response	to	treatments	in	obsessive-compulsive	disorder.	Article	in	submission	November	
2018	
Albert,	U.,	Barbaro,	F.,	Bramante,	S.,	Maina,	G.,	2018b.	Duration	of	untreated	illness,	dynamic	adherence	
and	response	to	treatment	in	OCD.	Eur	Psychiatry.Poster	abstract	48S,	S54.	
Alonso,	P.,	Segalas,	C.,	Real,	E.,	Pertusa,	A.,	Labad,	J.,	Jimenez-Murcia,	S.,	Jaurrieta,	N.,	Bueno,	B.,	Vallejo,	
J.,	Menchón,	 J.	M.,	 2010.	 Suicide	 in	 patients	 treated	 for	 obsessive-compulsive	 disorder:	 a	 prospective	
follow-up	study.	Journal	of	Affective	Disorders	124,	300-308.	
Altamura,	 A.C.	 ,	 Buoli,	 M.	 ,	 Albano,	 A.,	 Dell’Osso	 B.,	 2010.	 Age	 at	 onset	 and	 latency	 to	 treatment	
(duration	of	untreated	illness)	in	patients	with	mood	and	anxiety	disorders:	a	naturalistic	study.	Int	Clin	
Psychopharmacol	.	25,	172–	179.		
American	Psychiatric	Publishing,	2013,	Diagnostic	and	Statistical	Manual	of	Mental	Disorders,	Fifth	
Edition,	American	psychiatric	Publishing,	Washington,	DC.	
Angst,	J.,	Gamma,	A.,	Endrass,	J.,	Hantouche,	E.,	Goodwin,	R.,	Ajdacic,	V.,	Eich,	D.,	Rössler,	W.,	2005.	
Obsessive-compulsive	syndromes	and	disorders:	significance	of	comorbidity	with	bipolar	and	anxiety	
syndromes.	Eur	Arch	Psychiatry	Clin	Neurosci.	255(1),	65-7	
Anderson,	K.K.,	Voineskos,	A.,	Mulsant,	B.H.,	George,	T.P.,	Mckenzie,	K.J.,	2014.The	role	of	untreated	
psychosis	in	neurodegeneration:	a	review	of	hypothesized	mechanisms	of	neurotoxicity	in	first-episode	
psychosis.	Can	J	Psychiatry.	59(10),	513-7.	
Atmaca,	M.,	Yildirim,	H.,	Ozdemir,	H.,	Ozler,	S.,	Kara,	B.,	Ozler,	Z.,	Kanmaz,	E.,	Mermi,	O.,	Tezcan,	E.	2008.	
Hippocampus	 and	 amygdalar	 volumes	 in	 patients	with	 refractory	 obsessive-compulsive	 disorder.	 Prog	
Neuropsychopharmacol	Biol	Psychiatry.	32(5),1283-6.	
Attwells,	S.,	Setiawan,	E.,	Wilson,	A.A.,	Rusjan,	P.M.,	Mizrahi,	R.,	Miler,	L.,	Xu,	C.,	Richter,	M.A.	Kahn,	A.,	
Kish,	 S.J.,	 Houle,	 S.,	 Ravindran,	 L.,	Meyer	 J.H.,	 2017.	 Inflammation	 in	 the	Neurocircuitry	 of	Obsessive-
Compulsive	Disorder.	JAMA	Psychiatry		74(8),	833-840.	
Bebbington,	P.E	.,	1998.	Epidemiology	of	obsessive-compulsive	disorder.	Brit	J	Psychiatry,	Suppl	35,	2–	6.	
Benatti,	B.,	Camuri,	G.,	Dell'Osso,	B.,	Cremaschi,	L.,	Sembira,	E.,	Palazzo,	C.,	Oldani,	L.,	Dobrea,	C.,	Arici,	
C.,	Primavera,	D.,	Carpiniello,	B.,	Castellano,	F.,	Carrà,	G.,	Clerici,	M.,	Baldwin,	D.S.,	Altamura,	A.C.,	2016.	
Which	factors	influence	onset	and	latency	to	treatment	in	generalized	anxiety	disorder,	panic	disorder,	
and	obsessive-compulsive	disorder?	Int	Clin	Psychopharmacol.	31(6),	347-52.	
	
Berk,	M.,	Post,	R.,	Ratheesh,	A.,	Gliddon,	E.,	Singh,	A.,	Vieta,	E.,	Carvalho	,A.F.,	2017.	Staging	in	bipolar	
disorder:	from	theoretical	framework	to	clinical	utility.	World	Psychiatry,	16(3),	236-244.	doi:	
10.1002/wps.20441.	
Boedhoe,	P.S.W.,	Schmaal,	L.,	Abe,	Y.,	Alonso,	P.,	Ameis,	S.H.,	Anticevic,	A.,	Arnold,	P.D.,	Batistuzzo,	
M.C,,	Benedetti,	F.,	Beucke,	J.C,,	Bollettini,	I.,	Bose,	A.,	Brem,	S.,	Calvo,	A.,	Calvo,	R.,	Cheng,	Y.,	Cho,	
K.I.K.,	Ciullo,	V.,	Dallaspezia,	S.,	Denys,	D.,	Feusner,	J.D.,	Fitzgerald,	K.D.,	Fouche,	J.P.,	Fridgeirsson,	E.A.,	
Gruner,	P.,	Hanna,	G.L.,	Hibar,	D.P.,	Hoexter,	M.Q.,	Hu,	H.,	Huyser,	C.,	Jahanshad,	N.,	James,	A.,	
Kathmann,	N.,	Kaufmann,	C.,	Koch	,K.,	Kwon,	J.S.,	Lazaro,	L.,	Lochner,	C.,	Marsh,	R.,	Martínez-Zalacaín,	I.,	
Mataix-Cols,	D.,	Menchón,	J.M.,	Minuzzi,	L.,	Morer,	A.,	Nakamae,	T.,	Nakao,	T.,	Narayanaswamy,	J.C.,	
Nishida,	S.,	Nurmi,	E.,	O'Neill,	J.,	Piacentini	,J.,	Piras,	F.,	Reddy	,Y.C.J.,	Reess,	T.J.,	Sakai,	Y.,	Sato,	J.R.,	
Simpson,	H.B.,	Soreni,	N.,	Soriano-Mas,	C.,	Spalletta,	G.,	Stevens,	M.C.,	Szeszko,	P.R.,	Tolin,	D.F.,	van	
Wingen,	G.A.,	Venkatasubramanian,	G.,	Walitza,	S.,	Wang,	Z.,	Yun,	J.Y.,	Thompson,	P.M.,	Stein,	D.J.,	van	
den	Heuvel,	O.A.;	ENIGMA	OCD	Working	Group,	2018.	Cortical	Abnormalities	Associated	With	Pediatric	
and	Adult	Obsessive-Compulsive	Disorder:	Findings	From	the	ENIGMA	Obsessive-Compulsive	Disorder	
Working	Group.	Am	J	Psychiatry.	175(5),	453-462.	doi:	10.1176/appi.ajp.2017.17050485.		
Boedhoe,	P.S.W.,	Schmaal,	L.,	Abe,	Y.,	Ameis,	S.H.,	Arnold,	P.D.,	Batistuzzo,	M.C,,	Benedetti,	F.,	Beucke,	
J.C,,	Bollettini,	I.,	Bose,	A.,	Brem,	S.,	Calvo,	A.,	Calvo,	R.,	Cheng,	Y.,	Cho,	K.I.K.,		Dallaspezia,	S.,	Denys,	
D.,	Fitzgerald,K.D.,	Fouche,	J.P.,	Giménez,	M.,	Gruner,	P.,	Hanna,	G.L.,	Hibar,	D.P.,	Hoexter,	M.Q.,	Hu,	H.,	
Huyser,	C.,		Ikari,	K.,	Jahanshad,	N.,	Kathmann,	N.,	Kaufmann,	C.,	Koch	,K.,	Kwon,	J.S.,	Lazaro,	L.,	Lochner,	
C.,	Marsh,	R.,	Martínez-Zalacaín,	I.,	Mataix-Cols,	D.,	Menchón,	J.M.,	Minuzzi,	L.,	Nakamae,	T.,	Nakao,	T.,	
Narayanaswamy,	J.C.,		Piras,	F.,		Pittenger,	C.,	Reddy,	Y.C.,	Sato,	J.R.,	Simpson,	H.B.,	Soreni,	N.,	Soriano-
Mas,	C.,	Spalletta,	G.,	Stevens,	M.C.,	Szeszko,	P.R.,	Tolin,	D.F.,	van	Wingen,	G.A.,Venkatasubramanian,	
G.,	Walitza,	S.,	Wang,	Z.,		Xu,	J.,	Xu,	X.,	Yun,	J.Y.,	Zhao,	Q.,	ENIGMA	OCD	Working	Group,	Thompson,	
P.M.,	Stein,	D.J.,	van	den	Heuvel	,O.A.,	2017.	Distinct	Subcortical	Volume	Alterations	in	Pediatric	and	
Adult	OCD:	A	Worldwide	Meta-	and	Mega-Analysis.	Am	J	Psychiatry,	174(1),	60-69.	doi:	
10.1176/appi.ajp.2016.16020201.		
Brakoulias,	 V.,	 Starcevic,	 V.,	 Belloch,	 A.,	 Dell'osso,	 L.,	 Ferrão,	 Y.	 A.,	 Fontenelle,	 L.	 F.,	 Lochner,	 C.,	
Marazziti,	 D.,	 Martin,	 A.	 &	 Matsunaga,	 H.,	 2016a.	 International	 prescribing	 practices	 in	 obsessive–
compulsive	disorder	(OCD).	Hum	Psychopharmacol.	31(4),	319-24.	doi:	10.1002/hup.2541.	
Brakoulias,	V.,	Starcevic,	V.,	Martin,	A.,	Berle,	D.,	Milicevic,	D.	&	Viswasam,	K.	2016b.	The	familiality	of	
specific	symptoms	of	obsessive-compulsive	disorder.	Psychiatry	research,	239,	315-319.	
Brakoulias,	V.,	Starcevic,	V.,	Sammut,	P.,	Berle,	D.,	Milicevic,	D.,	Moses,	K.	&	Hannan,	A.	2011.	Obsessive-
compulsive	spectrum	disorders:	a	comorbidity	and	family	history	perspective.	Australasian	Psychiatry,	1-
5.	
Brakoulias,	 V.,	 Perkes,	 I.E.,	 Tsalamanios,	 E.,	 2018.	 A	 call	 for	 prevention	 and	 early	 intervention	 in	
obsessive-compulsive	disorder.	Early	Interv	Psychiatry.	.12(4):572-577.	
Burchi,	E.,	Hollander,	E.	and	Pallanti,	S.,	2018.	From	Treatment	Response	to	Recovery	–	a	Realistic	Goal	
in	 OCD.	 International	 Journal	 of	 Neuropsychopharmacology,	 21(11),1007-1013.	 doi:	
10.1093/ijnp/pyy0792018.	
Burchi,	 E.,	 Pallanti,	 S.,	 2018.	 Antibiotics	 for	 PANDAS?	 Limited	 Evidence:	 Review	 and	 Putative	
Mechanisms	 of	 Action.	 Prim	 Care	 Companion	 CNS	 Disord,	 May	 3,	 20(3).	 pii:	 17r02232.	 doi:	
10.4088/PCC.17r02232.	
	Carmi,	L.,	Fineberg	,N.,	Ben	Arush,	O.,	Zohar,	J.,	2019.	Epidemiology	of	OCD,	in:	Geddes	JR,	Andreasen	
NC	and	Goodwin	GM	(Eds),	New	Oxford	Textbook	of	Psychiatry	3edn.	Oxford	University	Press,	Oxford,	
UK.	In	press	November	2018.	
Chamberlain,	S.R.,	Blackwell,	A.D.,	Fineberg,	N.A.,	Robbins,	T.W.,	Sahakian,	B.J.,	2005.	The	
neuropsychology	of	obsessive	compulsive	disorder:	the	importance	of	failures	in	cognitive	and	
behavioural	inhibition	as	candidate	endophenotypic	markers.	Neurosci	Biobehav	Rev.	29(3),	399–419	
Chiarello,	F.,	Spitoni,	S.,	Hollander,	E.,	Matucci	Cerinic,	M.,	Pallanti	S.,	2017.	An	expert	opinion	on	
PANDAS/PANS:	highlights	and	controversies.	Int	J	Psychiatry	Clin	Pract.	21(2),	91-98.		
Coluccia,	A.,	Fagiolini,	A.,	Ferretti	,F.,	Pozza,	A.,	Costoloni,	G.,	Bolognesi	,S.,	Goracci,	A.,	2016.	Adult	
obsessive-compulsive	disorder	and	quality	of	life	outcomes:	A	systematic	review	and	meta-analysis.	
Asian	J	Psychiatr.	22,	41-52.	
Costa,	D.L.C.,	Diniz,	J.B.,	Requena,	G.,	Joaquim,	M.A.,	Pittenger,	C.,	Bloch,	M.H.,	Miguel,	E.C.,		Shavitt,	
R.G.	2017.	Randomized,	Double-Blind,	Placebo-Controlled	Trial	of	N-Acetylcysteine	Augmentation	for	
Treatment-Resistant	Obsessive-Compulsive	Disorder.	J	Clin	Psychiatry.	78(7):e766-e773.	doi:	
10.4088/JCP.16m11101.		
Dell'Osso,	B.,	Buoli,	M.,	Hollander,	E.,	Altamura	,A.C.,	2010.	Duration	of	untreated	illness	as	a	predictor	
of	treatment	response	and	remission	in	obsessive-compulsive	disorder.	World	J	Biol	Psychiatry,	
11(1),59-65.		
Dell’Osso,	B.,	Altamura,	A.C.,	2010.	Duration	of	untreated	psychosis	and	duration	of	untreated	illness:	
new	vistas.	CNS	Spectrums,	15(4),	238–46.	
Dell'osso,	B.,	Benatti,	B.,	Buoli,	M.,	Altamura,	A.C.,	Marazziti,	D.,	Hollander,	E.,	Fineberg,	N.,	Stein,	D.J.,	
Pallanti,	S.,	Nicolini,	H.,	Ameringen,	M.V.,	Lochner,	C.,	Hranov	,	G.,	Karamustafalioglu,	O.,	Hranov,	L.,	
Menchon,	J.M.,	Zohar,	J;	on	behalf	of	the	ICOCS	group,	2013a.The	influence	of	age	at	onset	and	duration	
of	illness	on	long-term	outcome	in	patients	with	obsessive-compulsive	disorder:	A	report	from	the	
International	College	of	Obsessive	Compulsive	Spectrum	Disorders	(ICOCS).	Eur	Neuropsychopharmacol.	
23(8),	865-71.	doi:	10.1016/j.euroneuro.2013.05.004.	Epub	2013	Jun	21.	
Dell’Osso,	B.,	Camuri,	G.,	Benatti,	B.,	Buoli,	M.,	Altamura,	A.C.,	2013b.	Differences	in	latency	to	first	
pharmacological	treatment	(duration	of	untreated	illness)	in	anxiety	disorders:	a	study	on	patients	with	
panic	disorder,	generalized	anxiety	disorder	and	obsessive-compulsive	disorder.	Early	intervention	in	
psychiatry,	7(4),	374–80.	
Dell'Osso,	B.,	Glick,	I.D.,	Baldwin,	D.S.,	Altamura,	A.C.,	2013c.	Can	long-term	outcomes	be	improved	by	
shortening	the	duration	of	untreated	illness	in	psychiatric	disorders?	A	conceptual	framework.	
Psychopathology,46(1),14-21.	
Dell'Osso,	B.,	Benatti	,B.,	Oldani,	L.,	Spagnolin,	G.,	Altamura,	A.C.,	2015.	Differences	in	duration	of	
untreated	illness,	duration,	and	severity	of	illness	among	clinical	phenotypes	of	obsessive-compulsive	
disorder.	CNS	Spectrums,20(5),	474-8.		
Dell'Osso,	B.,	Benatti,	B.,	Hollander,	E.,	Fineberg,	N.,	Stein,	D.J.,	Lochner,	C.,	Nicolin,i	H.,	Lanzagorta,	N.,	
Palazzo,	C.,	Altamura,	A.C.,	Marazziti,	D.,	Pallanti,	S.,	Van	Ameringen,	M.,	Karamustafalioglu,	O.,	
Drummond,	L.M.,	Hranov,	L.,	Figee,	M.,	Grant	,J.E.,	Zohar,	J.,	Denys,	D.,	Menchon,	J.M.,	2016	a.	
Childhood,	adolescent	and	adult	age	at	onset	and	related	clinical	correlates	in	obsessive-compulsive	
disorder:	a	report	from	the	International	College	of	Obsessive-Compulsive	Spectrum	Disorders	(ICOCS).	
Int	J	Psychiatry	Clin	Pract.	19,	1-8.	PMID:27433835	
Dell'Osso,	B.,	Oldani,	L.,	Camuri,	G.,	Benatti,	B.,	Grancini,	B.,	Arici,	C.,	Cremasch	,	L.,	Palazzo,	M.,	
Spagnolin,	G.,	Dobrea,	C.,	Altamura,	A.C.,	2016b.	Reduced	duration	of	untreated	illness	over	time	in	
patients	with	schizophrenia	spectrum,	mood	and	anxiety	disorders.	Psychiatry	Clin	Neurosci.70(5),202-
10.		
Dell'Osso,	B.,	Benatt,i	B.,	Hollander,	E.,	Altamura,	A.C.,	2017.	Clinical	features	associated	with	increased	
severity	of	illness	in	tertiary	clinic	referred	patients	with	obsessive	compulsive	disorder.	Int	J	Psychiatry	
Clin	Pract.	21(2),131-136.	
de	la	Fuente-Tomas,	L.,	Sánchez-Autet,	M.,	García-Álvarez	L.,	González-Blanco,	L.,	Velasco,	Á.,	Sáiz	
Martínez	,	P.A.,	Garcia-Portilla,	M.P.,	Bobes,	J.,		2018.	Clinical	staging	in	severe	mental	disorders;	bipolar	
disorder,	depression	and	schizophrenia.	Rev	Psiquiatr	Salud	Ment.	Oct	9.	pii:	S1888-9891(18)30073-9.	
doi:	10.1016/j.rpsm.2018.08.002.	[Epub	ahead	of	print]	English	
De	Luca,	V.	,	Gershenzon,	V.	,	Burroughs,	E.,	Javaid,	N.,	Richter,	M.A	.,	2011.	Age	at	onset	in	Canadian	
OCD	patients:	mixture	analysis	and	systematic	comparison	with	other	studies	.	J	Affect	Dis.	133,	300–	
304.	
Diniz,	J.B.,	Shavitt,	R.G.,	Fossaluza,	V.,	Koran,	L.,	Pereira,	C.A.,	Miguel,	.EC.,	2011.	A	double-blind,	
randomized,	controlled	trial	of	fluoxetine	plus	quetiapine	or	clomipramine	versus	fluoxetine	plus	
placebo	for	obsessive-compulsive	disorder.	J	Clin	Psychopharmacol.	31(6):763-8.	doi:	
10.1097/JCP.0b013e3182367aee.		
Drummond,	L.M.,	1993.	The	treatment	of	severe,	chronic,	resistant	obsessive-compulsive	disorder.	An	
evaluation	of	an	in-patient	programme	using	behavioural	psychotherapy	in	combination	with	other	
treatments.	Br	J	Psychiatry,	163,	223-9	
Dupont,	R.L.,	Rice,	D.P.,	Shiraki,	S.,	Rowland	,C.R.,		1995.	Economic	costs	of	obsessive-compulsive	
disorder.	Med	Interface,		8,	102-109.	
Durkin,	M.S.,	Elsabbagh,	M.,	Barbaro,	J.,	Gladstone,	M.,	Happe,	F.,	Hoekstra,	R.A.,	Lee,	L.C.,	Rattazzi,	A.,	
Stapel-Wax,	J.,	Stone,	W.L.,	Tager-Flusberg,	H.,	Thurm,	A.,	Tomlinson,	M.,	Shih,	A.,	2015.	Autism	
screening	and	diagnosis	in	low	resource	settings:	Challenges	and	opportunities	to	enhance	research	and	
services	worldwide.	Autism	research:	official	journal	of	the	International	Society	for	Autism	Research,	
8(5),	473-476.	
Eaton,	W.W.,	Martins,	S.S.,	Nestadt,	G.,	Bienvenu,	O.J.,	Clarke,	D.,	Alexandre,	P.,	2008.	The	burden	of	
mental	disorders.	Epidemiol	Rev.	30,	1-14.	
Edwards,	J.,	McGorry,	P.,	2002.	Multi-component	early	intervention	-	models	of	good	practice.	
In:	Edwards	J,	McGorry	PD	editor(s).	Implementing	Early	Intervention	in	Psychosis.	London:	Martin	
Dunitz,	63-84.	
Eisen,	J.L.,	Goodman,	W.K.,	Keller,	M.B., Warshaw,	M.G.,	DeMarco,	L.M.,	Luce,	D.D.,	Rasmussen,	
S.A.,		2013.	Patterns	of	remission	and	relapse	in	obsessive-compulsive	disorder:	a	2-year	prospective	
study.	J	Clin	Psychiatry,	74(3),	233–239.	doi:		10.4088/JCP.12m07657	
Fagundes	Junior,	H.M.,	Desviat,	M.,	Silva,	P.R.,	2016.	Psychiatric	Reform	in	Rio	de	Janeiro:	the	current	
situation	and	future	perspectives.	Ciencia	&	saude	coletiva,21(5),1449-1460.	
Fatori,	D.,	de	Bragança	Pereira,	C.A.,	Asbahr,	F.R.,	Requena,	G.,	Alvarenga,	P.G.,	de	Mathis,	M.A.,	Rohde,	
L.A.,	Leckman,	J.F.,	March,	J.S.,	Polanczyk,	G.V.,	Miguel,	E.C.,	Shavitt,	R.G.,	2018.	Adaptive	treatment	
strategies	for	children	and	adolescents	with	Obsessive-Compulsive	Disorder:	A	sequential	multiple	
assignment	randomized	trial.J	Anxiety	Disord.	58,	42-50.	doi:	10.1016/j.janxdis.2018.07.002.		
Faurholt-Jepsen,	M.,	Bauer,	M.,	Kessing,	L.V.,	2018.	Smartphone-based	objective	monitoring	in	bipolar	
disorder:	status	and	considerations.	Int	J	Bipolar	Disord.	6(1),	6.	doi:	10.1186/s40345-017-0110-8.		
Fineberg,	N.A.,	Hengartner,	M.P.,	Bergbaum,	C.E.,	Gale,	T.,	Gamma,	A.,	Ajdacic-Gross,	V.,	Rössler,	W.,	
Angst,	J.,	2013a.	A	Prospective	Population-Based	Cohort	Study	Of	The	Prevalence,	Incidence	And	Impact	
Of	Obsessive-Compulsive	Symptomatology.	Int	J	Psychiatry	Clin	Pract.	17(3),	170-8.	doi:	
10.3109/13651501.2012.755206.		
Fineberg,	N.A.,	Hengartner,	M.P.,	Bergbaum,	C.E.,	Gale,	T.,	Rössler,	W.,	Angst,	J.,	2013b.	Lifetime	
comorbidity	of	obsessive-compulsive	disorder	and	sub-threshold	obsessive-compulsive	symptomatology	
in	the	community:	impact,	prevalence,	socio-demographic	and	clinical	characteristics.	Int	J	Psychiatry	
Clin	Pract.	17(3),188-96.	doi:	10.3109/13651501.2013.777745.		
Fineberg,	N.A.,	Hengartner,	M.P.,	Bergbaum,	C.E.,	Gale,	T.,	Rössler,	W.,	Angst,	J.,	2013c.	Remission	of	
obsessive-compulsive	disorders	and	syndromes;	evidence	from	a	prospective	community	cohort	study	
over	thirty	years.	Int	J	Psychiatry	Clin	Pract.	17(3),	179-87.	doi:	10.3109/13651501.2013.777744.		
Fineberg,	N.A.,	Reghunandanan	,S.,	Simpson,	H.B.,	Phillips,	K.A.,	Richter,	M.A.,	Matthews,	K.,	Stein,	D.J.,	
Sareen,	J.,	Brown,	A.,	Sookman,	D.,	2015.	Accreditation	Task	Force	of	The	Canadian	Institute	for	
Obsessive	Compulsive	Disorders.	Obsessive-compulsive	disorder	(OCD):	Practical	strategies	for	
pharmacological	and	somatic	treatment	in	adults.	Psychiatry	Res.	227(1),114-25.	doi:	
10.1016/j.psychres.2014.12.003.		
Fineberg,	N.A.,	Baldwin,	D.S.,	Drummond,	L.M.,	Wyatt,	S.,	Hanson,	J.,	Gopi,	S.,	Kaur,	S.,	Reid	,J.,	Marwah,	
V.,	Sachdev,	R.A.,	Pampaloni	,I.,	Shahper,	S.,	Varlakova,	Y.,	Mpavaenda,	D.,	Manson,	C.,	O'Leary,	C.,	
Irvine,	K.,	Monji-Patel,	D.,	Shodunke,	A.,	Dyer,	T.,	Dymond	,A.,	Barton,	G.,	Wellsted,	D.,	2018.	Optimal	
treatment	for	obsessive	compulsive	disorder:	a	randomized	controlled	feasibility	study	of	the	clinical-
effectiveness	and	cost-effectiveness	of	cognitive-behavioural	therapy,	selective	serotonin	reuptake	
inhibitors	and	their	combination	in	the	management	of	obsessive	compulsive	disorder.	Int	Clin	
Psychopharmacol.	33(6),	334-348.	doi:	10.1097/YIC.0000000000000237.		
Frankovich,	J.,	Swedo,	S.,	Murphy,	T.,	Dale,	R.C.,	Agalliu,	D.,	Williams,	K.,	Daines,	M.,	Hornig,	M.,	Chugani,	
H.,	Sanger,	T.,	Muscal,	E.,	Pasternack,	M.,	Cooperstock,	M.,	Gans,	H.,	Zhang,	Y.,	Cunningham,	M.,	
Bernstein,	G.,	Bromberg	,R.,	Willett,	T.,	Brown,	K.,	Farhadian	,B.,	Chang,	K.,	Geller	,D.,	Hernandez,	J.,	
Sherr,	J.,	Shaw,	R.,	Latimer,	E.,	Leckman,	J.,	Thienemann,	M.,	2017.	PANS/PANDAS	Consortium.	Clinical	
Management	of	Pediatric	Acute-Onset	Neuropsychiatric	Syndrome:	Part	II-Use	of	Immunomodulatory	
Therapies.	Journal	of	Child	and	Adolescent	Psychopharmacology,	27(7),	574-593.	
Freeman,	J.	B.,	Choate-Summers,	M.	L.,	Moore,	P.	S.,	Garcia,	A.	M.,	Sapyta,	J.	J.,	Leonard,	H.	L.	&	Franklin,	
M.	E.	2007.	Cognitive	behavioral	treatment	for	young	children	with	obsessive-compulsive	disorder.	
Biological	Psychiatry,	61,	337-343.	
Fullana,	M.A.,	Mataix-Cols,	D.	,	Caspi,	A.,	Harrington,	H.,	Grisham,	J.R.	,	Moffi	tt,	T.E.,	Poulton,	R	.,	2009.	
Obsessions	and	compulsions	in	the	community:	prevalence,	interference,	help-seeking,	developmental	
stability,	and	co-occurring	psychiatric	conditions	.	Am	J	Psychiatry,	166,	329–	336.	
Fullana,	M.A.	,	Vilagut,	G.	,	Rojas-Farreras,	S.	,	Mataix-Cols,	D.,	de	Graaf	,R.	,	Demyttenaere,	K.,	2010.	
Obsessive-compulsive	symptom	dimensions	in	the	general	population:	results	from	an	epidemiological	
study	in	six	European	countries.	J	Aff	ect	Dis.	124,	291–	299.	
Garcia,	A.M.,	Sapyta	J.J.,	Moore,	P.S.,	Freeman,	J.B.,	Franklin,	M.E.,	March,	J.S.,	Foa,	E.B.,	2010.	
Predictors	and	moderators	of	treatment	outcome	in	the	Pediatric	Obsessive	Compulsive	Treatment	
Study	(POTS	I).	J	Am	Acad	Child	Adolesc	Psychiatry,	49(10),1024-1033		
Geller,	D.,	Biederman,	J.,	Faraone,	S.V.,	Frazier,	J.,	Coffey,	B.,	Kim,	G.,	Bellordre,	C.A.,	2000.	Clinical	
correlates	of	obsessive	compulsive	disorder	in	children	and	adolescents	referred	to	specialized	and	non-
specialized	clinical	settings.	Depress	Anxiety,	11,	163-68.	doi:	10.1002/1520-6394(2000)11:4<163::AID-
DA3>3.0.CO;2-3.	
Geller,	D.,	Biederman,	J.,	Faraone,	S.V.,	Agranat,	A.,	Cradock,	K.,	Hagermoser,	L.,	Kim,	G.,	Frazier,J.,	
Coffey,	B.J.,	2001a.	Developmental	aspects	of	obsessive	compulsive	disorder:	Findings	in	children,	
adolescents,	and	adults.	J	Nerv	Ment	Dis.	189,	471-77.	doi:	0022-3018/01/1897-471.	
Geller,	D.,	Biederman,	J.,	Faraone,	S.V.,		Bellordre,	C.A.,	Kim,	G.S.,	Hagermoser,	L.,	Cradock,	K.,	Frazier,	J.,	
Coffey,	B.J.,	2001b.	Disentangling	chronological	age	from	age	of	onset	in	children	and	adolescents	with	
obsessive-compulsive	disorder.	Int	J	Neuropsychopharmacol.	4,	169-78.	doi:	
10.1017/S1461145701002395.	
Geller,	D.A.,	Biederman,	J.,	Stewart,S.E.,	Mullin,	B.,	Martin,	A.,	Spencer,	T.,	Faraone,	S.V.,		2003.	Which	
SSRI?	A	meta-analysis	of	pharmacotherapy	trials	in	pediatric	obsessive-compulsive	disorder.	Am	J	
Psychiatry,	160,	1919-28.	doi:	10.1176/appi.ajp.160.11.1919.	
Geller,	D.,	Petty,	C.,	Vivas,	F.,	Johnson,	J.,	Pauls,	D.,	Biederman	J.,	2007.	Examining	the	relationship	
between	obsessive-compulsive	disorder	and	attention-deficit/hyperactivity	disorder	in	children	and	
adolescents:	A	familial	risk	analysis.	Biol	Psychiatry,61,	316-21.	doi:	10.1016/j.biopsych.2006.03.083.	
Geller,	D.A.,	Wieland,	N.,	Carey,	K.,	Vivas,	F.,	Petty,	C.R.,	Johnson,	J.,	Reichert,	E.,	Pauls,	D.,	Biederman,	J.,	
2008.	Perinatal	factors	affecting	expression	of	obsessive	compulsive	disorder	in	children	and	
adolescents.	J	Child	Adolesc	Psychopharmacol.	18,	373-79.	doi:	10.1089/cap.2007.0112.		
Geller,	D.A.,	Abramovitch,	A.,	Mittelman,	A.,	Stark,	A.,	Ramsey,	K.,	Cooperman,	A.,	Baer,	L.,	Stewart,	S.E.,	
2017.	Neurocognitive	Function	in	Pediatric	Obsessive-Compulsive	Disorder.	World	Journal	of	Biological	
Psychiatry,	16,	1-26.	doi:	10.1080/15622975.2017.1282173.		
Glazier,	K.,	Calixte,	R.M.,	Rothschild,	R.,	Pinto,	A.,	2013.	High	rates	of	OCD	symptom	misidentification	by	
mental	health	professionals.	Ann	Clin	Psychiatry,25(3),	201-9.	
Gnanave,l	S.,	Sharan,	P.,	Khandelwal,	S.,	Sharma,	U.,	Jagannathan,	N.R.,	2014.	Neurochemicals	measured	
by	(1)H-MR	spectroscopy:	putative	vulnerability	biomarkers	for	obsessive	compulsive	disorder.	MAGMA.	
27(5),	407-17.	
Gobin,	V.,	Van	Steendam,	K.,	Denys,	D.,	Deforce,	D.,	2014.	Selective	serotonin	reuptake	 inhibitors	as	a	
novel	class	of	immunosuppressants.	Int	Immunopharmacol.	20(1),	148-56.		
Goodman,	W.,	Rasmussen,	S.	,	Leckman,	J.	F.,	1995.	A	family	study	of	obsessive-compulsive	disorder.	Am	
J	Psychiatry,	152,	76-84.	
Grant,	J.E.	,	Mancebo,	M.C.	,	Pinto,	A.	,	Williams,	K.A.	,	Eisen,	J.L.	,	Rasmussen,	S.A	.,	2007	.	Late-onset	
obsessive	compulsive	disorder:	clinical	characteristics	and	psychiatric	comorbidity	.	Psychiatry	Res.	152	
:21	–	27		
Grisham,	J.R.	,	Fullana,	M.A.,	Mataix-Cols,	D.	,	Moffi	tt,	T.E.,	Caspi,	A.,	Poulton,	R.,	2011	.	Risk	factors	
prospectively	associated	with	adult	obsessive	compulsive	symptom	dimensions	and	obsessive-
compulsive	disorder.	Psych	Med,	15,	1–	12.	
Grünblatt,	 E.,	Oneda,	B.,	 Ekici,	A.B.,	Ball,	 J.,	Geissler,	 J.,	Uebe,	 S.,	Romanos,	M.,	Rauch,	A.,	Walitza,	 S.,	
2017.	 High	 resolution	 chromosomal	 microarray	 analysis	 in	 paediatric	 obsessive-compulsive	 disorder.	
BMC	Med	Genomics,10(1),	68.	doi:	10.1186/s12920-017-0299-5.	
Grünblatt,	E.,	Marinova,	Z,,	Roth,	A.,	Gardini,	E.,	Ball,	J.,	Geissler,	J.,	Wojdacz,	TK.,	Romanos	M.,	Walitza	
S.,	2018.	Combining	genetic	and	epigenetic	parameters	of	the	serotonin	transporter	gene	in	obsessive-
compulsive	disorder.	J	Psychiatr	Res.	96,	209-217.	
Heyman,	I.	,	Fombonne,	E.	,	Simmons,	H.	,	Ford,	T.	,	Meltzer,	H	.,	Goodman	.,	2001.	Prevalence	of	
obsessive-compulsive	disorder	in	the	British	nationwide	survey	of	child	mental	health.	Brit	J	Psychiatry,	
179,	324	–	329	.	
Hirschtritt,	M.E.,	Bloch,	M.H.,	Mathews,	C.A.,	2017.	Obsessive-Compulsive	Disorder:	Advances	in	
Diagnosis	and	Treatment.	JAMA,	317(13),1358-1367.	
Højgaard,	D.	R.,	Hybel,	K.	A.,	Ivarsson,	T.,	Skarphedinsson,	G.,	Becker	Nissen,	J.	B.,	Weidle,	B., 	Melin,	K.,	
Torp,	N.C.,	Valderhaug,	R.,	Dahl,	K.,	Mortensen,	E.L.,	Compton,	S.,	Jensen,	S.,	Lenhard,	F.,	Thomsen,	P.H.,	
Mortensen,	E.	L.,	2017.	One-year	outcome	for	responders	of	cognitive-behavioral	therapy	for	pediatric	
obsessive-compulsive	disorder.	Journal	of	the	American	Academy	of	Child	&	Adolescent	
Psychiatry,	56(11),	940-947.	
Hollander,	E.,	Stein,	D.J.,	Fineberg,	N.A.,	Marteau,	F.,	Legault,	M.,	2010.	Quality	of	life	outcomes	in	
patients	with	obsessive-compulsive	disorder:	relationship	to	treatment	response	and	symptom	relapse.	J	
Clin	Psychiatry,		71,	784-792.	
Hollander,	E.,	Doernberg,	E.,	Shavitt,	R.,	Waterman,	R.J.,	Soreni	,	N.,	Veltman	,D.J.,	Sahakian,	B.J.,	
Fineberg	,N.A.,	2016.	The	cost	and	impact	of	compulsivity:	A	research	perspective	European	
Neuropsychopharmacology	,	26	(5),	800	–	809.	
House,	S.J.,	Tripathi,	S.P.,	Knight,	B.T.,	Morris,	N.,	Newport,	D.J.,	Stowe,	Z.N.,	2016.	Obsessive-
compulsive	disorder	in	pregnancy	and	the	postpartum	period:	course	of	illness	and	obstetrical	outcome.	
Arch	Womens	Ment	Health.		19(1),	3-10.	doi:	10.1007/s00737-015-0542-z.		
Ioannidis,	K.,	Treder,	M.	S.,	Chamberlain,	S.	R.,	Kiraly,	F.,	Redden,	S.	A.,	Stein,	D.	J.,	Lochner,	C.,		Grant,	J.	
E.,	2018.	Problematic	internet	use	as	an	age-related	multifaceted	problem:	Evidence	from	a	two-site	
survey.	Addictive	Behaviors,	81,	157–166.	http://doi.org/10.1016/J.ADDBEH.2018.02.017	
Jakubovski,	E.,	Diniz,	J.B.,	Valerio,	C.,	Fossaluza,	V.,	Belotto-Silva,	C.,	Gorenstein,	C.,	Miguel,	E.,	Shavitt,	
RG.,	2013.	Clinical	predictors	of	long-term	outcome	in	obsessive-compulsive	disorder.	Depress	Anxiety.	
30(8):763-72.	doi:	10.1002/da.22013.	Epub	2012	Oct	25.	PubMed	PMID:	23109056.	
Kamath,	P.,	Reddy,	Y.	&	Kandavel,	T.,	2007.	Suicidal	behavior	in	obsessive-compulsive	disorder.	Journal	
of	Clinical	Psychiatry,	68,	1741-1750.	
Kamath,	 P.,	 Reddy,	 Y.C.,	 Kandavel,	 T.,	 2007.	 Suicidal	 behavior	 in	 obsessive-compulsive	 disorder.	 J	 Clin	
Psychiatry.	68(11),	1741-50	
Kantak,	 P.A.,	 Bobrow,	 D.N.,	 Nyby,	 J.G.,	 2014.	 Obsessive–compulsive	 like	 behaviors	 in	 house	mice	 are	
attenuated	by	a	probiotic	(Lactobacillus	rhamnosus	GG).	Behav	Pharmacol.	25(1),	71–79.	
Kessler,	R.C	,	Berglund,	P.,	Demler,	O.,	Jin	,R.,	Merikangas,	K.R	.,	Walters,	E.E	.,2005a.	Lifetime	prevalence	
and	age-of-onset	distributions	of	DSM-IV	disorders	in	the	National	Comorbidity	Survey	Replication.	Arch	
Gen	Psychiatry,	62,	593–	602.	
Kessler,	R.C.,	Chiu	W.T.,	Demler,	O.,	Merikangas,	K.R	.,	Walters,	E.E.,	2005b.	Prevalence,	severity,	and	
comorbidity	of	12-month	DSM-IV	disorders	in	the	National	Comorbidity	Survey	Replication.	Arch	Gen	
Psychiatry,	62,	617–	627.	
Kessler,	R.C., Ormel,	J.,	Petukhova,	M.,	McLaughlin,	K.A.,	Green,	J.G.,	Russo,	L.J.,	Stein	,D.J.,	Zaslavsky,	
A.M.,	Aguilar-Gaxiola,	S.,	Alonso,	J.,	Andrade,	L.,	Benjet,	C.,	de	Girolamo,	G.,	de	Graaf,	R.,	Demyttenaere,	
K.,	Fayyad,	J.,	Haro,	J.M.,	Hu,	C.Y.,	Karam,	A.,	Lee,	S.,	Lepine,	J.P.,	Matchsinger,	H.,	Mihaescu-Pintia,	
C.,	Posada-Villa,	J.,	Sagar,	R.,	Ustün,	T.B.,	2011.	Development	of	lifetime	comorbidity	in	the	World	Health	
Organization	world	mental	health	surveys.	Arch	Gen	Psychiatry,		68(1),	90-100.		
Kichuk,	S.A.,	Torres,	A.R.,	Fontenelle,	L.F.,	Rosário,	M.C.,	Shavitt,	R.G.,	Miguel	,E.C.,	Pittenger,	C.,	Bloch	
M.H.,	2013.	Symptom	dimensions	are	associated	with	age	of	onset	and	clinical	course	of	obsessive-
compulsive	disorder.	Prog	Neuropsychopharmacol	Biol	Psychiatry,	44,	233-9.	
Knapp,	M.,	Henderson,	J.,	Patel,	A.,	2002.	Costs	of	Obsessive–	Compulsive	Disorder:	A	Review,	in:		Maj	
M,	Sartorius	N,	Okasha	A,	Zohar	J	(Eds.).	Obsessive–Compulsive	Disorder.	Wiley,	New	York,	NY,	pp253–	
99.	
Kohn,	R.,	Saxena,	S.,	Levav,	I.,	Saraceno,	B.,	2004.	The	treatment	gap	in	mental	health	care.	Bull	World	
Health	Organ.	82(11),	858-66.	
Labad,	J.	,	Menchon,	J.M.,	Alonso,	P.	,	Segalas,	C.,	Jimenez,	S.,	Jaurrieta,	N., 	Leckman,	J.F.,	Vallejo,	J.,	
2008.	Gender	differences	in	obsessive-compulsive	symptom	dimensions.	Depress	Anxiety,	25,		832–	838.	
Macy,	A.S.,	Theo,	J.N.,	Kaufmann,	S.C.,	Ghazzaoui	,R.B.,	Pawlowski,	P.A.,	Fakhry,	H.I.,	Cassmassi,	
B.J.,	IsHak,	W.W.,	2013.	Quality	of	life	in	obsessive	compulsive	disorder.	CNS	Spectr.	18(1),	21-33.	
Maina,	G.,	Albert,	U.,	Bogetto,	F.,	2001.	Relapses	after	discontinuation	of	drug	associated	with	increased	
resistance	to	treatment	in	obsessive-compulsive	disorder.	Int	Clin	Psychopharmacol.	16(1),	33-8.	
Maina,	G.,	Salvi,	V.,	Tiezzi,	M.	N.,	Albert,	U.	&	Bogetto,	F.,	2007.	Is	OCD	at	risk	for	suicide?	A	case-control	
study.	Clinical	Neuropsychiatry:	Journal	of	Treatment	Evaluation,	4,	117-121.	
Mancebo,	M.C.,	Greenberg,	B.,	Grant,	J.E.,	Pinto,	A.,	Eisen,	J.L.,	Dyck,	I.,	Rasmussen,	S.A.,	2008.	
Correlates	of	occupational	disability	in	a	clinical	sample	of	obsessive-compulsive	disorder.	Compr	
Psychiatry,	49,	43-50.	
Mancebo,	M.C.,	Boisseau,	C.L.,	Garnaat	,S.L.,	Eisen,	J.L.,	Greenberg,	B.D.,	Sibrava,	N.J.,	Stout	
,R.L.,	Rasmussen,	S.A.,	2014.	Long-term	course	of	pediatric	obsessive-compulsive	disorder:	3	years	of	
prospective	follow-up.	Compr	Psychiatry.		55(7),	1498-504.	doi:	10.1016/j.comppsych.2014.04.010.		
Mazmanian,	M.,	Yates,	J.,Orlikowski	,W.,	2017.	Published	Online:30	Nov	
https://journals.aom.org/doi/abs/10.5465/ambpp.2006.27169074	
Menchón,	J.M.,	van	Ameringen,	M.,	Dell'Osso,	B.,	Denys,	D.,	Figee,	M.,	Grant,	J.E.,	Hollander,	E.,	
Marazziti,	D.,	Nicolini,	H.,	Pallanti,	S.,	Ruck,	C.,	Shavitt,	R.,	Stein,	D.J.,	Andersson,	E.,	Bipeta,	R.,	Cath,	D.C.,	
Drummond,	L.M.,	Feusner,	J.,	Geller,	D.A.,	Hranov,	G.,	Lochner,	C.,	Matsunaga,	H.,	McCabe,	R.E.,	
Mpavaenda,	D.,	Nakamae,	T.,	O'Kearney,	R.,	Pasquini,	M.,	Pérez	Rivera,	R.,	Poyurovsky,	M.,	Real,	E.,	do	
Rosário,	M.C.,	Soreni	,N.,	Swinson,	R.P.,	Vulink,	N.,	Zohar,	J.,	Fineberg,	N.,	2016.	Standards	of	care	for	
obsessive-compulsive	disorder	centres.	Int	J	Psychiatry	Clin	Pract.	20(3),	204-8.	
Merlo,	L.	J.,	Lehmkuhl,	H.	D.,	Geffken,	G.	R.,	Storch,	E.	A.,	2009.	Decreased	family	accommodation	
associated	with	improved	therapy	outcome	in	pediatric	obsessive–compulsive	disorder.	Journal	of	
consulting	and	clinical	psychology,	77,	355.	
Micali,	N.,	Heyman,	 I.,	 Perez,	M.,	Hilton,	 K.,	Nakatani,	 E.,	 Turner,	 C.,	Mataix-Cols,	D.,	 2010.	 Long-term	
outcomes	of	obsessive–compulsive	disorder:	follow-up	of	142	children	and	adolescents.	British	Journal	
of	Psychiatry.	197,	128-134.	
Miguel,	E.C.,	Ferrao,	Y.A.,	Rosario,	M.C.,	de	Mathis,	M.A.,	Rodrigues	Torres,	A.,	Fontenelle,	L.F.,		Hounie,	
A.G.,	 Shavitt,R.G.,	 Cordioli,	 A.V.,	 Gonzalez,	 C.H.,Petribú,	 C.,	 Diniz,JB.,	 Malavazzi,	 D.M.,	 Torresan,	 R.C.,	
Raffin,	A.L.,	Meyer,	E.,	Braga,	D.T.,	Borcato,	S.,	a	Valério,	C.,	Gropo,	L.N.,da	Silva	Prado,H.,	Alliende	Perin,	
E.,	Santos,	S.L.,	Copque,	H.,	Corrêa	Borges,	M.,	Prazeres	Lopes,	A.,	da	Silva,	E.D.,	The	Brazilian	Research	
Consortium	on	Obsessive-Compulsive	Spectrum	Disorders.,	2008.	The	Brazilian	Research	Consortium	on	
Obsessive-Compulsive	 Spectrum	 Disorders:	 recruitment,	 assessment	 instruments,	 methods	 for	 the	
development	 of	 multicenter	 collaborative	 studies	 and	 preliminary	 results.	 Revista	 brasileira	 de	
psiquiatria	(Sao	Paulo,	Brazil	:	1999),	30(3),	185-196.	
Nair,	A.,	Wong,	Y.L.,	Barrow,	F.,	Heyman,	I.,	Clark,	B.,	Krebs,	G.,	2015.	Has	the	first-line	management	of	
paediatric	OCD	improved	 following	 the	 introduction	 of	NICE	 guidelines?	 Arch	Dis	 Child.	 100(4),	 416-7.	
doi:	10.1136/archdischild-2014-307900.		
National	Institute	for	Health	and	Clinical	Excellence	(NICE).	2006.	Obsessive	compulsive	disorder:	Core	
interventions	in	the	treatment	of	obsessive	compulsive	disorder	and	body	dysmorphic	disorder.	National	
Clinical	Practice	Guideline	Number	31	(https://www.nice.org.uk/guidance/cg31/evidence/full-guideline-
pdf-194883373)		
Nicholson,	T.	R.,	Ferdinando,	S.,	Krishnaiah,	R.	B.,	Anhoury,	S.,	Lennox,	B.	R.,	Mataix-Cols,	D.,	Cleare,	A.,	
Veale,	D.	M.,	Drummond,	L.	M.	&	Fineberg,	N.	A.,	2012.	Prevalence	of	anti-basal	ganglia	antibodies	in	
adult	obsessive–compulsive	disorder:	cross-sectional	study.	The	British	Journal	of	Psychiatry,	200,	381-
386.	
	Nissen,	J.B.,	Thomsen,	P.H.,	2008.	Clinicians'	views	on	clinical	examination	and	treatment	of	children	
and	adolescents	with	obsessive-compulsive	disorder	(OCD).	A	Danish	national	survey	study.	Nord	J	
Psychiatry,	62(4),	309-14.	doi:	10.1080/08039480801984065.	
Orefici,	G.,	Cardona,	F.,	Cox	,C.J.,	Cunningham,	M.W.	,	2016.	Pediatric	Autoimmune	Neuropsychiatric	
Disorders	Associated	with	Streptococcal	Infections	(PANDAS),	in:	Ferretti	JJ,	Stevens	DL,	Fischetti	VA	
(Eds.).	Streptococcus	pyogenes	:	Basic	Biology	to	Clinical	Manifestations	[Internet].	Oklahoma	City	(OK):	
University	of	Oklahoma	Health	Sciences	Center.	
Parra-Cardona,	R.,	Leijten,	P.,	Lachman,	J.M.,	Mejía,	A.,	Baumann,	A.A.,	Amador	Buenabad,	N.G.,	Cluver,	
L.,	 Doubt,	 J.,	 Gardner,	 F.,	 Hutchings,	 J.,	 Ward,	 C.L.,	 Wessels,	 I.M.,	 Calam,	 R.,	 Chavira,	 V.,	 Domenech	
Rodríguez,	M.M.,	 2018.	 Strengthening	 a	 Culture	 of	 Prevention	 in	 Low-	 and	Middle-Income	 Countries:	
Balancing	 Scientific	 Expectations	 and	Contextual	 Realities.	 Prev	 Sci.	 2018	 Jul	 30.	 doi:	 10.1007/s11121-
018-0935-0.	[Epub	ahead	of	print]PMID:30058025	
Pearlman,	D.M.,	Vora,	H.S.,	Marquis,	B.G.,	Najjar,	S.,	Dudley,	L.A.,	2014.	Anti-basal	ganglia	antibodies	in	
primary	obsessive-compulsive	disorder:	systematic	review	and	meta-analysis.	Br	J	Psychiatry,	205(1),	8-
16.		
Peris,	 T.S.,	 Bergman,	 R.L.,	 Langley,	 A.,	 Chang,	 S.,	 McCracken,	 J.T.,	 Piacentini,	 J.,	 2008.	 Correlates	 of	
accommodation	of	pediatric	obsessive	 compulsive	disorder:	 parent,	 child,	 and	 family	 characteristics.	 J	
Am	Acad	Child	Adolesc	Psychiatry,		47(10),	1173-1181.	
Peris,	 T.S.,	Rozenman,	 M.S.,	Sugar,	 C.A.,	McCracken,	 J.T.,	Piacentini,	J.,	 2017.	 Targeted	 Family	
Intervention	 for	 Complex	Cases	of	 Pediatric	Obsessive-Compulsive	Disorder:	A	Randomized	Controlled	
Trial,		56(12),	1034-1042.	doi:	10.1016/j.jaac.2017.10.008.		
Pollitt	J.,1957.	Natural	history	of	obsessional	states.	Brit	Med	J.	1,	194	–	198	.	
Poyraz,	C.A.,	Turan,	Ş.,	Sağlam,	N.G.,	Batun,	G.Ç.,	Yassa,	A.,	Duran,	A.,	2015.	Factors	associated	with	the	
duration	of	untreated	illness	among	patients	with	obsessive	compulsive	disorder.	Compr	Psychiatry,	58,	
88-93.	
Quagliariello,	A.,	Del	Chierico,	F.,	Russo,	A.,	Reddel,	S.,	Conte,	G.,	Lopetuso,	L.R.,	Ianiro,	G.,	Dallapiccola,	
B.,	 Cardona,	 F.,	Gasbarrini,	A.,	 Putignani,	 L.,	 2018.	Gut	Microbiota	Profiling	 and	Gut-Brain	Crosstalk	 in	
Children	 Affected	 by	 Pediatric	 Acute-Onset	 Neuropsychiatric	 Syndrome	 and	 Pediatric	 Autoimmune	
Neuropsychiatric	Disorders	Associated	With	Streptococcal	Infections.	Front	Microbiol.	9,	675.	
Rao,	 N.P.,	 Venkatasubramanian,	 G.,	 Ravi,	 V.,	 Kalmady,	 S.,	Cherian,	 A.,	Yc	 J.R.,	 2015.	 Plasma	 cytokine	
abnormalities	 in	 drug-naïve,	 comorbidity-free	 obsessive-compulsive	 disorder.	 Psychiatry	 Res.	 229(3),	
949-52.		
Rapoport,	J.L.,	Inoff-Germain,	G.,	Weissman,	M.M.,	Greenwald,	S.,	Narrow	,W.E.,	Jensen,	P.S,	Lahey,	
B.B.,	Canino,	G.,	2000.	Childhood	obsessive–compulsive	disorder	in	the	NIMH	MECA	study:	Parent	
versus	child	identification	of	cases.	J	Anxiety	Disord.	14,	535–48	
Reddy,	Y.C.,	Rao,	N.P.,	Khanna,	S.,	2010.	An	overview	of	Indian	research	in	obsessive	compulsive	
disorder.	Indian	journal	of	psychiatry,	52(Suppl	1),	S200-209.	
Robins,	L.N.,	Helzer,	J.E.,	Weissman,	M.M.,	Orvaschel,	H.,	Gruenberg,	E.,	Burke,	J.D.	Jr.,	Regier,	
D.A.,1984.	Lifetime	prevalence	of	specifi	c	psychiatric	disorders	in	three	sites.	Arch	Gen	Psychiatry,	41,	
949–	958.	
Rodríguez,	N.,	Morer,	A.,	González-Navarro,	E.A., Serra-Pages,	C.,	Boloc,	D.,	Torres,	T.,	García-Cerro,	S.,	
Mas,	S.,	Gassó,	P.,	Lázaro,	L.,	2017.	Inflammatory	dysregulation	of	monocytes	in	pediatric	patients	with	
obsessive-compulsive	disorder.	J	Neuroinflammation,		14(1),		261.		
Rosario-Campos,	M.C.,	Leckman,	J.,	Mercandante,	M.T.,	Shavitt,	R.G.,	da	Sila	Prado,	H.,	Zamignani,	D.,	
Miguel,	E.,	2001.	Adults	with	early-onset	obsessive	compulsive	disorder.	Am	J	Psychiatry,	158,	1899-
1903.	
Rufer,	M.,	Hand,	I.,	Alsleben,	H.,	Braatz,	A.,	Ortmann,	J.,	Katenkamp,	B.,	Fricke,	S.,	Peter,	H.	(2005).	Long-
term	course	and	outcome	of	obsessive-compulsive	patients	after	cognitive-behavioral	therapy	in	
combination	with	either	fluvoxamine	or	placebo.	European	Archives	of	Psychiatry	and	Clinical	
Neuroscience,	255(2),	121–128.		
Ruscio,	A.M.,	Stein,	D.J.,	Chiu,	W.T.,	Kessler,	R.C.,	2010.The	epidemiology	of	obsessive-compulsive	
disorder	in	the	National	Comorbidity	Survey	Replication.	Mol	Psychiatry.	15(1),	53-63.	doi:	
10.1038/mp.2008.94.	
Schrag,	A.	,	Martino,	D.,	Apter,	A.,	Ball,	J.,	Bartolini,	E.,	Benaroya-Milshtein,	N.,	Buttiglione,	M.,	Cardona,	
F.,	Creti,	R.,	Efstratiou,	A.,	Gariup,	M.,	Georgitsi,	M.,	Hedderly,	T.,	Heyman,	I.,	Margarit,	I.,	Mir,	P.,	Moll,	
N.,	Morer,	A.,	Müller,	N.,	Müller-Vahl,	K.,	Münchau,	A.,	Orefici,	G.,	Plessen,	K.J.,	Porcelli,	C.,	Paschou,	
P.,	Rizzo,	R.,	Roessner,	V.,	Schwarz,	M.J.,	Steinberg,	T.,	Tagwerker	Gloor,	F.,	Tarnok,	Z.,	Walitza,	
S.,	Dietrich,	A.,	Hoekstra,	P.J.,	EMTICS	Collaborative	Group,	2018.	European	Multicentre	Tics	in	Children	
Studies	(EMTICS):	protocol	for	two	cohort	studies	to	assess	risk	factors	for	tic	onset	and	exacerbation	in	
children	and	adolescents.	Eur	Child	Adolesc	Psychiatry.	2018	Jul	7.	doi:	10.1007/s00787-018-1190-4.	
[Epub	ahead	of	print]	
Skoog,	G.,	Skoog,	I.,	1999.	A	40-Year	Follow-up	of	Patients	With	Obsessive-compulsive	Disorder.	Arch	
Gen	Psychiatry,	56(2),	121-127.	doi:10.1001/archpsyc.56.2.121	
Skapinakis,	P.,	Caldwell,	D.,	Hollingworth,	W.,	Bryden,	P.,	Fineberg,	N.,	Salkovskis,	P.,	Welton,	N.,	Baxter,	
H.,	Kessler,	D.,	Churchill,	R.,	Lewis,	G.,	2016a.	Pharmacological	and	psychotherapeutic	interventions	for	
management	 of	 obsessive-compulsive	 disorder	 in	 adults:	 a	 systematic	 review	 and	 network	 meta-
analysis.	Lancet	Psychiatry,	3(8),	730-739.	
Skapinakis,	P.,	Caldwell,	D.,	Hollingworth,	W.,	Bryden,	P.,	Fineberg,	N.,	Salkovskis,	P.,	Welton,	N.,	Baxter,	
H.,	Kessler,	D.,	Churchill,	R.,	Lewis,	G.,	2016b.	A	systematic	review	of	the	clinical	effectiveness	and	cost-
effectiveness	of	pharmacological	and	psychological	interventions	for	the	management	of	obsessive-
compulsive	disorder	in	children/adolescents	and	adults.	Health	Technol	Assess.	20,	1-392.	
Snider,	 L.	 A.,	 Lougee,	 L.,	 Slattery,	 M.,	 Grant,	 P.	 &	 Swedo,	 S.	 E.,	 2005.	 Antibiotic	 prophylaxis	 with	
azithromycin	or	penicillin	for	childhood-onset	neuropsychiatric	disorders.	Biological	Psychiatry,	57,	788-
792.	
Spartz,	E.J.,	Freeman,	G.M.	Jr,	Brown,	K.,	Farhadian,	B.,	Thienemann,	M.,	Frankovich,	J.,	2017.	Course	of	
Neuropsychiatric	Symptoms	After	Introduction	and	Removal	of	Nonsteroidal	Anti-Inflammatory	Drugs:	A	
Pediatric	Observational	Study.	J	Child	Adolesc	Psychopharmacol.	27(7),		652-659.		
Stengler,	K.,	Olbrich,	S.,	Heider,	D.,	Dietrich,	S.,	Riedel-Heller,	S.,	Jahn,	I.,	2013.	Mental	health	treatment	
seeking	 among	 patients	with	OCD:	 impact	 of	 age	 of	 onset.	 Soc	 Psychiatry	 Psychiatr	 Epidemiol.	 48(5),	
813-9.	
Stewart,	S.E.,	Rosario,	M.C.,	Brown,	T.A.,	Carter,	A.S.,	Leckman,	J.F.,	Sukhodolsky,	D.,	Katsovitch,	L.,	King,	
R.,	Geller,	D.,	Pauls,	D.L.,	2007.	Principal	components	analysis	of	obsessive-compulsive	disorder	
symptoms	in	children	and	adolescents.	Biol	Psychiatry	61,	285-91.	doi:	10.1016/j.biopsych.2006.08.040.	
Stewart,	S.E.,	Geller,	D.A.,	Jenike,	M.,	Pauls,	D.,	Shaw,	D.,	Mullin,	B.,	Faraone	,S.V.,	2004.	Long-term	
outcome	of	pediatric	obsessive-compulsive	disorder:	A	meta-analysis	and	qualitative	review	of	the	
literature.	Acta	Psychiatr	Scand.	110,	4-13.	doi:	10.1111/j.1600-0447.2004.00302.x.	
Storch,	E.A.,	Muroff,	J.,	Lewin,	A.B.,	Geller,	D.,	Ross,	A.,	McCarthy,	K.,	Morgan,	J.,	Murphy,	T.K.,	Frost,	R.,	
Steketee,	G.,	2011.	Development	and	preliminary	psychometric	evaluation	of	the	Children’s	Saving	
Inventory.	Child	Psychiatry	Hum	Dev.	42,	166-82.	doi:	10.1007/s10578-010-0207-0	
Storch,	E.A.,	De	Nadai	,A.S.,	Jacob,	M.L.,	Lewin,	A.B.,	Muroff,	J.,	Eisen,	J.,	Abramowitz,	J.S.,	Geller,	D.A.,	
Murphy,	T.K.,	2014.	Phenomenology	and	correlates	of	insight	in	pediatric	obsessive-compulsive	
disorder.	Compr	Psychiatry.	55,	613-20.	doi:	10.1016/j.comppsych.2013.09.014.	
Storch,	E.A.,	Small,	B.J.,	McGuire,	J.F.,	Murphy,	T.K.,	Wilhelm,	S.,	Geller,	D.A.,	2018.	Quality	of	Life	in	
Children	and	Youth	with	Obsessive	Compulsive	Disorder.	Journal	of	Child	and	Adolescent	
Psychopharmacology,	28,	104-110.		
Subramaniam,	M.,	Soh,	P.,	Vaingankar,	J.A.,	Picco,	L.,	Chong	,S.A.,	2013.	Quality	of	life	in	obsessive–
compulsive	disorder:	impact	of	the	disorder	and	of	treatment.	CNS	Drugs,	27,	367–83.	
Swedo,	 S.E.,	 Leonard,	 H.L.,	 Garvey,	M.,	Mittleman,	 B.,	 Allen,	 A.J.,	 Perlmutter,	 S.,	 Lougee,	 L.,	 Dow,	 S.,	
Zamkoff,	 J.,	 Dubbert,	 B.K.,	 1998.	 Pediatric	 autoimmune	 neuropsychiatric	 disorders	 associated	 with	
streptococcal	infections:	clinical	description	of	the	first	50	cases.	Am	J	Psychiatry,	155(2),	264-271.	
The	National	Institute	of	Mental	Health	(2017).	Technology	and	the	Future	of	Mental	Health	Treatment.	
Retrieved	from:	https://www.nimh.nih.gov/health/topics/technology-and-the-future-of-mental-health-
treatment/index.shtml	
Taylor,	S.,	2011.	Early	versus	late	onset	obsessive-compulsive	disorder:	evidence	for	distinct	subtypes.	
Clin	Psychol	Rev.	31(7):,	1083-100.	doi:	10.1016/j.cpr.2011.06.007.	PMID:21820387	
Tylee,	D.S.,	Sun,	J.,	Hess,	J.L.,	Tahir,	M.A.,	Sharma,	E.,	Malik,	R.,	Worrall,	B.B.,	Levine,	A.J.,	Martinson,	J.J.,	
Nejentsev,	S.,	Speed,	D.,	Fischer,	A.,	Mick,	E.,	Walker,	B.R.,	Crawford,	A.,	Grant,	S.F.A.,	Polychronakos,	C.,	
Bradfield,	J.P.,	Sleiman,	P.M.A,	Hakonarson,	H.,	Ellinghaus,	E.,	Elder,	J.T.,	Tsoi,	L.C.,	Trembath,	R.C.,	
Barker,	J.N.,	Franke,	A.,	Dehghan,	A.,	23	and	Me	Research	Team,	Inflammation	Working	Group	of	the	
CHARGE	Consortium,	METASTROKE	Consortium	of	the	International	Stroke	Genetics	Consortium,	
Netherlands	Twin	Registry,	neuroCHARGE	Working	Group,	Obsessive	Compulsive	and	Tourette	
Syndrome	Working	Group	of	the	Psychiatric	Genomics	Consortium,	Faraone,	S.V.,	Glatt	,S.J.	,	2018.	
Genetic	correlations	among	psychiatric	and	immune-related	phenotypes	based	on	genome-wide	
association	data.	Am	J	Med	Genet	B	Neuropsychiatr	Genet. 177(7),	641-657.	doi:	10.1002/ajmg.b.32652.		
van	Grootheest,	D.S.,	Bartels,	M.,	Cath,	D.C.,	Beekman,	A.T.,	Hudziak,	J.J.,	Boomsma,	D.I.,	2007.	Genetic	
and	environmental	contributions	underlying	stability	in	childhood	obsessive-compulsive	behavior.	Biol	
Psychiatry,	61(3),	308-15.		
Viswanath,	B.,	Narayanaswamy,	J.C.,	Cherian,	A.V.,	Reddy,	Y.C.J.,	Math,	S.B.,	2011.	Is	familial	Obsessive-
Compulsive	disorder	different	from	sporadic	Obsessive-Compulsive	Disorder?	A	comparison	of	clinical	
characteristics,	comorbidity	and	treatment	response.	Psychopathology,	44(2),	83-89.	
Volkmar,	F.,	Siegel,	M.,	Woodbury-Smith,	M.,	King,	B.,	McCracken,	J.,	State,	M.,	Child,	A.	A.,	2014.	
Practice	parameter	for	the	assessment	and	treatment	of	children	and	adolescents	with	autism	spectrum	
disorder.	Journal	of	the	American	Academy	of	Child	&	Adolescent	Psychiatry,	53(2),	237-257.	
Walitza,	S.,	Marinova,	Z.,	Grünblatt,	E.,	Lazic,	S.E.,	Remschmidt,	H.,	Vloet,	T.D.,	Wendland,	J.R.,	2014.	Trio	
study	and	meta-analysis	support	the	association	of	genetic	variation	at	the	serotonin	transporter	with	
early-onset	obsessive-compulsive	disorder.	Neurosci	Lett.	580,	100-3.	doi:	10.1016/j.neulet.2014.07.038.	
PMID:	25093702	
Walitza,	S.,	Wendland,	J.R.	,	Gruenblatt,	E.	,	Warnke,	A.	,	Sontag,	T.A.	,	Tucha,	O.,	Lange,	K.W	.,	2010.	
Genetics	of	early-onset	obsessive-compulsive	disorder.	Eur	Child	Adolesc	Psychiat	19,	227–	235.	
Walitza,	S.,	Zellmann,	H.,	Irblich,	B.,	Lange,	K.W.,	Tucha,	O.,	Hemminger,	U.,	Wucherer,	K.,	Rost,	V.,	
Reinecker	,H.,	Wewetzer,	C.,	Warnke,	A.,	2008.	Children	and	adolescents	with	obsessive-compulsive	
disorder	and	comorbid	attention-deficit/hyperactivity	disorder:	preliminary	results	of	a	prospective	
follow-up	study.	J	Neural	Transm	(Vienna),115(2),	187-90.	doi:	10.1007/s00702-007-0841-2.		
Wang,	L.Y.,	Chen,	S.F.,	Chiang,	J.H.,	Hsu	C.Y.,	Shen,	Y.C.,	2018.	Systemic	autoimmune	diseases	are	
associated	with	an	increased	risk	of	obsessive–compulsive	disorder:	a	nationwide	population-based	
cohort	study.	Social	Psychiatry	and	Psychiatric	Epidemiology,	published	online	7th	November	2018.	
https://doi.org/10.1007/s00127-018-1622-y.	
Weissman,	M.M.	,	Bland,	R.C.	,	Canino,	G.J.	,	Greenwald,	S.	,	Hwu,	H.G.	,	Lee,	C.K., Newman,	S.C.,	Oakley-
Browne,	M.A.,	Rubio-Stipec,	M.,	Wickramaratne,	P.J.,	1994.	The	cross	national	epidemiology	of	
obsessive	compulsive	disorder.	Cross	National	Collaborative	Group	.	J	Clin	Psychiatry,	55,	5–	10.	
Williams,	K.E.,	Koran,	L.M.,	1997.	Obsessive-compulsive	disorder	in	pregnancy,	the	puerperium,	and	the	
premenstruum.	J	Clin	Psychiatry,	58(7),	330-4	
Williams,	K.A.,	Swedo,	S.E.,	Farmer,	C.A.,	Grantz,	H.,	Grant,	P.J.,	D'Souza,	P.,	Hommer,	R.,	Katsovich,	L.,	
King,	 R.A.,	 Leckman,	 J.F.,	 2016.	 Randomized,	 Controlled	 Trial	 of	 Intravenous	 Immunoglobulin	 for	
Pediatric	Autoimmune	Neuropsychiatric	Disorders	Associated	with	Streptococcal	 Infections.	 J	Am	Acad	
Child	Adolesc	Psychiatry,	55(10),	860-867	
Wittchen,	H.U.,	Jacob,i	F.,	Rehm,	J.,	Gustavsson,	A.,	Svensson,	M.,	Jönsson,	B.,	Olesen,	J.,	Allgulander,	C.,	
Alonso,	J.,	Faravelli,	C.,	Fratiglioni,	L.,	Jennum,	P.,	Lieb,	R.,	Maercker	,A.,	van	Os,	J.,	Preisig,	M.,	Salvador-
Carulla,	L.,	Simon,	R.,	Steinhausen,	H.C.,	2011.	The	size	and	burden	of	mental	disorders	and	other	
disorders	of	the	brain	in	Europe	2010.	Eur	Neuropsychopharmacol.	21,	655–679.	
World	Health	Organization	Report	(2011).	mHealth:	New	horizons	for	health	through	mobile	
technologies.	World	Health	Organization,	64(7),	66-71.	
World	Health	Organization.	(2018).	The	precautionary	principle:	Public	health,	protection	of	children	and	
sustainability.			Retrieved	April	15,	2018,	from	
http://www.who.int/hia/examples/overview/whohia076/en/	
Zellmann,	H.,	Jans,	T.,	Irblich,	B.,	Hemminger,	U.,	Reinecker,	H.,	Sauer,	C.,	Lange,	K.W.,	Tucha,	O.,	
Wewetzer	,C.,	Warnke,	A.,	Walitza,	S.,	2009	[Children	and	adolescents	with	obsessive-compulsive	
disorders].		Z	Kinder	Jugendpsychiatr	Psychother.	37(3),	173-82.	doi:	10.1024/1422-4917.37.3.173.	
[Article	in	German]		
Zilhão,	N.R.,	Abdellaoui	,A.,	Smit,	D.J.A.,	Cath,	D.C.,	Hottenga,	J.J.,	Boomsma,	D.I.,	2018.	Polygenic	
prediction	of	obsessive	compulsive	symptoms.	Mol	Psychiatry,	23(2),	168-169.	
	
	
	
	
	
	
	
